Search Result
Results for "
Anti-convulsant
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
61
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15068
-
|
FG9202
|
iGluR
|
Neurological Disease
|
|
NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
|
-
-
- HY-B0211
-
-
-
- HY-B0184
-
|
W-554; ADD-03055
|
iGluR
|
Neurological Disease
|
|
Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
-
- HY-B0211A
-
-
-
- HY-15068A
-
|
FG9202 disodium
|
iGluR
|
Neurological Disease
|
|
NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
|
-
-
- HY-Y1673
-
-
-
- HY-N1469
-
-
-
- HY-114703
-
-
-
- HY-B0246S
-
-
-
- HY-W090292
-
|
|
Drug Intermediate
|
Neurological Disease
|
|
Olivetolic acid is a biosynthetic precursor of cannabinol acid (CBGA). Olivetolic acid exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Olivetolic acid can be used for the study of convulsion .
|
-
-
- HY-B1184
-
-
-
- HY-P1334
-
-
-
- HY-B1185
-
-
-
- HY-B1642
-
|
Peganone
|
Sodium Channel
|
Neurological Disease
|
|
Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin .
|
-
-
- HY-108506
-
|
BIA 2-005; GP 47779
|
Sodium Channel
|
Neurological Disease
|
|
Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-B0246S2
-
-
-
- HY-W294348
-
-
-
- HY-B1376
-
|
Mesuximide; Celontin
|
Calcium Channel
|
Neurological Disease
|
|
Methsuximide is an anticonvulsant agent. Methsuximide is effective in petit mal, psychomotor and focal motor attacks .
|
-
-
- HY-103230
-
-
-
- HY-115366
-
-
-
- HY-P1334A
-
-
-
- HY-100797
-
|
(±)-CPP
|
iGluR
|
Neurological Disease
|
|
(RS)-CPP ((±)-CPP) is a potent and selective NMDA antagonist. (RS)-CPP inhibits central neuron responses, and has anticonvulsant activity .
|
-
-
- HY-14953
-
|
AWD 131-138
|
GABA Receptor
|
Neurological Disease
|
|
Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.
|
-
-
- HY-141795
-
|
Co 134444
|
Drug Derivative
|
Neurological Disease
|
|
Posovolone (Co 134444) is an orally active, neuroactive steroid. Posovolone has anticonvulsant and anxiolytic-like activity as well as ataxic effects .
|
-
-
- HY-108504
-
|
V 102862
|
Sodium Channel
|
Neurological Disease
|
|
Co 102862 (V 102862) is a potent, broad-spectrum, state-dependent Na + channel blocker. Co 102862 is also an orally active anticonvulsant .
|
-
-
- HY-100379
-
-
-
- HY-B0246S1
-
-
-
- HY-133486
-
-
-
- HY-Y1373S1
-
|
Hexahydrobenzoic acid-d11
|
Endogenous Metabolite
|
Neurological Disease
|
|
Cyclohexanecarboxylic acid-d11 is the deuterium labeled Cyclohexanecarboxylic acid . Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .
|
-
-
- HY-100377
-
|
Anticonvulsant 7903
|
Others
|
Neurological Disease
|
|
Lvguidingan is a potent anticonvulsant agent. Lvguidingan also has sedative-hypnotic, tranquilizing, and muscle-relaxing actions. Lvguidingan can be used as antiepileptic agent .
|
-
-
- HY-22183
-
-
-
- HY-U00307
-
-
-
- HY-U00102
-
-
-
- HY-114692
-
-
-
- HY-116944
-
-
-
- HY-121393
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Imidazenil is a partial positive allosteric modulator of GABAA receptors with anxiolytic, antipanic and anticonvulsant activities.
|
-
-
- HY-W010383
-
-
-
- HY-Y1373R
-
|
Hexahydrobenzoic acid (Standard)
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
|
Cyclohexanecarboxylic acid (Standard) is the analytical standard of Cyclohexanecarboxylic acid. This product is intended for research and analytical applications. Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .
|
-
-
- HY-B0184A
-
|
W-554 hydrate; ADD-03055 hydrate
|
iGluR
|
Neurological Disease
|
|
Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
|
-
-
- HY-W749797
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Nitrazolam is a benzodiazepine compound, that may exhibit CNS depressant properties as traditional benzodiazepines, including sedation, hypnosis, anxiolysis, and anticonvulsant effects, by acting on GABA receptors .
|
-
-
- HY-160978
-
|
KC-7507 free base
|
GABA Receptor
|
Neurological Disease
|
|
Timelotem (KC-7507 free base) is a representative of a class of 1, 2-cyclo1, 4-benzodiazepines. Timelotem shows significant antipsychotic properties. Timelotem produces sedative, anti-anxiety and anti-convulsant effects by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Timelotem can be used in studies of schizophrenia and other mental disorders .
|
-
-
- HY-154436
-
-
-
- HY-170930
-
|
|
GABA Receptor
Sodium Channel
|
Neurological Disease
|
|
Anticonvulsant agent 9 (compound 4f) is an α1β2γ2 GABAA receptors activator. Anticonvulsant agent 9 activatesα1β2γ2 GABAA receptors with an EC50 of 1.24 μM. Anticonvulsant agent 9 inhibits the inactivation of Nav1.2 channels. Anticonvulsant agent 9 exhibits significant anticonvulsant activities .
|
-
-
- HY-136471
-
-
-
- HY-162757
-
|
|
GABA Receptor
Sodium Channel
|
Neurological Disease
|
|
Anticonvulsant agent 5 (Compound 5c) exhibits high affinity for GABAA receptors and NaV1.3 receptors. Anticonvulsant agent 5 shows anticonvulsant efficacy in mice psychomotor epilepsy test with an ED50 of 107 mg/kg. Anticonvulsant agent 5 exhibits neuroprotective activity against Kainic acid (HY-N2309) with an IC50 of 113 μM. Anticonvulsant agent 5 is blood-brain barrier (BBB) penetrable .
|
-
-
- HY-170833
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Anticonvulsant agent 8 (compound D4) is an anticonvulsant agent that inhibits GABAA currents with ED50 values of 2.23 and 24.60 mg/kg in the maximum electroshock (MES) and pentylenetetrazol (PTZ) tests in mouse models, respectively .
|
-
-
- HY-173181
-
|
|
Keap1-Nrf2
|
Neurological Disease
|
|
Anticonvulsant agent 10 (Compound 6d) is an inhibitor targeting the Keap1-Nrf2 interaction, with a potent ED50 of 0.04 mmol/kg. By inhibiting Keap1-Nrf2 binding and activating the Nrf2/ARE pathway, Anticonvulsant agent 10 exerts anticonvulsant and neuroprotective effects, making it suitable for research in antiepileptic and neuroprotective studies .
|
-
-
- HY-U00348
-
|
4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide
|
Others
|
Neurological Disease
|
|
Anticonvulsant agent 1 is an anticonvulsant agent extracted from patent WO2001062726A2, Compound 156.
|
-
-
- HY-114300
-
|
|
GABA Receptor
|
Neurological Disease
|
|
DSP-0565 (compound 17a) is a strong, broad-spectrum anti-epileptic agent (AED) candidate with unique GABAergic function. DSP-0565 shows anti-convulsant activity in various models (scPTZ, MES, 6 Hz and amygdala kindling) with good safety margin .
|
-
-
- HY-101827
-
-
- HY-105569
-
-
- HY-116826
-
-
- HY-105059
-
-
- HY-123229
-
-
- HY-133773
-
-
- HY-119950
-
-
- HY-126043
-
-
- HY-119461
-
-
- HY-106670
-
-
- HY-105845
-
-
- HY-118490
-
-
- HY-119915
-
|
M-144; Themisone
|
Others
|
Neurological Disease
|
|
Atrolactamide (M-144) is a potent anticonvulsant. Atrolactamide can be used for the research of epilepsy .
|
-
- HY-106747
-
-
- HY-107710
-
-
- HY-170717
-
-
- HY-105844
-
-
- HY-114705
-
-
- HY-106716
-
-
- HY-125555
-
-
- HY-167936
-
|
|
Liposome
|
Neurological Disease
|
|
cis-AY 9944 is a cholesterol synthesis inhibitor, exhibiting anticonvulsant activity that influences the dynamics of spike and wave discharges in EEG recordings.
|
-
- HY-N0491
-
|
(-)-Lupinidine sulfate
|
nAChR
|
Neurological Disease
|
|
(-)-Sparteine (sulfate) is a quinolizidine alkaloid that can be extracted from Lupinus. (-)-Sparteine (sulfate) inhibits the release of acetylcholine and has anticonvulsant effects .
|
-
- HY-101353
-
|
(-)-LY 235959
|
iGluR
|
Neurological Disease
|
|
LY 235959 is a competitive N-methyl-D-aspartate (NMDA)-receptor antagonist. LY 235959 potentiates the anticonvulsant action of antiepileptics .
|
-
- HY-101240
-
-
- HY-133160
-
|
VPA-HA
|
Drug Derivative
|
Neurological Disease
|
|
Valproic acid hydroxamate (VPA-HA) has shown anticonvulsant activity in a mouse neural tube defect model, without any teratogenic effects .
|
-
- HY-114703R
-
-
- HY-B1184S1
-
-
- HY-U00315S
-
|
Gidasepam-d5; Hidazepam-d5; Hydazepam-d5
|
GABA Receptor
|
Neurological Disease
|
|
Gidazepam-d5 is a deuterium labeled Gidazepam. Gidazepam is an agonist of GABA receptor channels (GABA RCs), and has anticonvulsant effect .
|
-
- HY-W721596
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
Pentadecanoyl ethanolamide is derivate of endougenous lipid amides, the N-acylethanolamines. Pentadecanoyl ethanolamide exhibits anticonvulsant efficacy in electroshocked mice without significant toxicity .
|
-
- HY-120306
-
|
|
AP-1
|
Neurological Disease
|
|
HHL-6 can regulate the overexpression of c-Fos and BDNF proteins. HHL-6 has potent anticonvulsant and antiepileptogenic effects .
|
-
- HY-171253
-
-
- HY-B1184S2
-
-
- HY-100963
-
-
- HY-172005
-
|
|
Sodium Channel
|
Neurological Disease
|
|
10,11-Dihydroxycarbamazepine is a metabolite of the anticonvulsant Carbamazepine (HY-B0246). Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker .
|
-
- HY-B1184S
-
-
- HY-107323
-
|
QM 6008; Thiadipone; Tiadipone
|
GABA Receptor
|
Neurological Disease
|
|
Bentazepam (Thiadipone) is a compound with short-action anxiolytic effect. Bentazepam shows anticonvulsant and sedative properties. Bentazepam can be used for the research of depressive disorder and anxiety .
|
-
- HY-101387A
-
|
|
mGluR
|
Neurological Disease
|
|
ACPT-II is an antagonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects .
|
-
- HY-120240
-
|
|
Others
|
Others
|
|
AND-302 is a small molecule anticonvulsant with activity in preventing glutamate- or hydrogen peroxide-induced cell death and decreased neuronal viability in in vitro hippocampal cultures.
|
-
- HY-182023
-
|
|
Reactive Oxygen Species (ROS)
GABA Receptor
|
Neurological Disease
|
|
Anticonvulsant agent 11 (Compound 8b) is an anticonvulsant agent. Anticonvulsant agent 11 exerts neuroprotective effects by enhancing cell viability and reducing ROS levels. Anticonvulsant agent 11 induces the expression of GABAA α1, resulting in neuronal hyperpolarization. Anticonvulsant agent 11 increases the number of neurite-bearing cells and the length of neurites. Anticonvulsant agent 11 exhibits dose-dependent anticonvulsant effects in mice. Anticonvulsant agent 11 can be used for the research of epilepsy .
|
-
- HY-170801
-
|
|
Drug Derivative
|
Neurological Disease
|
|
Anticonvulsant agent 7 (Compound 19) is an orally active broad-spectrum anticonvulsant that demonstrates excellent anticonvulsive activity in both the MES (maximal electroshock seizure) and 6 Hz epilepsy modelsmouse .
|
-
- HY-171182
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
D3017 is the main metabolite of D2624, which has oral bioactivity and anti-convulsant effects. D3017 ED50 value is 1.5 mg/kg in mice, and it can be used for research on severe generalized tonic-clonic seizures (grand mal) and complex partial epilepsy .
|
-
- HY-W744266
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
9α,10α-Epoxyhexahydrocannabinol is an active metabolite of delta 9-tetrahydrocannabinol. 9α,10α-Epoxyhexahydrocannabinol has anti-convulsant activity. 9α,10α-Epoxyhexahydrocannabinol reduces body temperature, prolongs pentobarbital-induced sleep, and exerts anticonvulsant activity against pentylenetetrazol-induced seizures in mice .
|
-
- HY-A0177
-
|
|
GABA Receptor
|
Inflammation/Immunology
|
|
Fominoben is a type of benzamide-based antitussive agent. Fominoben works by acting on the central nervous system to increase alveolar ventilation, thereby improving the blood oxygen levels in patients with pulmonary diseases (COLD). Fominoben can bind to the benzodiazepine receptor binding sites in the brain and also has anti-anxiety and anti-convulsant effects. Fominoben can be used in research on hypoxemia.
|
-
- HY-B1185R
-
|
N-Benzyl-3-chloropropionamide (Standard)
|
Drug Derivative
Reference Standards
|
Neurological Disease
|
|
Beclamide (Standard) is the analytical standard of Beclamide. This product is intended for research and analytical applications. Beclamide is an active molecule with anticonvulsant activity, used as an anticonvulsant drug.
|
-
- HY-165469
-
-
- HY-105059A
-
-
- HY-121155
-
-
- HY-W653803
-
-
- HY-105340
-
|
|
iGluR
|
Neurological Disease
|
|
MDL 27266 is an orally active NMDA receptor antagonist with neuroprotective effect. MDL 27266 is a broad-spectrum anticonvulsant agent .
|
-
- HY-Y1373S
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
Cyclohexanecarboxylic acid-d1 is the deuterium labeled Cyclohexanecarboxylic acid . Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .
|
-
- HY-W580836
-
-
- HY-W580812
-
-
- HY-124148
-
-
- HY-12503
-
CFM-2
1 Publications Verification
|
iGluR
|
Neurological Disease
Cancer
|
|
CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .
|
-
- HY-Y1373
-
-
- HY-108506S1
-
-
- HY-W436270
-
|
|
Dopamine Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Bulbocapnine hydrochloride, an aporphine alkaloid, is a dopamine receptor inhibitor. Bulbocapnine hydrochloride inhibits dopamine synthesis. Bulbocapnine hydrochloride also has neuroleptic-like, anticonvulsant and antinociceptive effects .
|
-
- HY-15436
-
|
|
iGluR
|
Neurological Disease
|
|
L-687414 is an orally active glycine-site NMDA receptor antagonist or low-potency partial agonist. L-687414 has anticonvulsant activity .
|
-
- HY-19082
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Y-23684 is a partial agonist of benzodiazepine receptor (BZR) with anticonvulsant and anxiolytic activities. Y-23684 can be used in the research of treatment of anxiety disorders .
|
-
- HY-101387
-
|
|
mGluR
|
Neurological Disease
|
|
rel-ACPT-I is an agonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects .
|
-
- HY-108506S
-
|
BIA 2-005-d3; GP 47779-d3
|
Sodium Channel
|
Neurological Disease
|
|
Licarbazepine-d3 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
- HY-129408
-
|
|
GABA Receptor
|
Neurological Disease
|
|
SGE-516 is a neuroactive steroid that is a potent positive allosteric modulator of synaptic and extra-synaptic GABAA receptors. SGE-516 has anticonvulsant activity .
|
-
- HY-B1274
-
-
- HY-114703S1
-
-
- HY-B1184R
-
-
- HY-Z16070
-
|
|
Drug Derivative
|
Cardiovascular Disease
Neurological Disease
|
|
Hydronopol is a saturated alcohol terpene derivative. Hydronopol shows central inhibitory, anticonvulsant, analgesic, anticholinergic and antihypertensive activities. Hydronopol can be used for the researches of neurological and cardiovascular disease .
|
-
- HY-B1376R
-
|
Mesuximide (Standard); Celontin (Standard)
|
Calcium Channel
Reference Standards
|
Neurological Disease
|
|
Methsuximide (Standard) is the analytical standard of Methsuximide. This product is intended for research and analytical applications. Methsuximide is an anticonvulsant agent. Methsuximide is effective in petit mal, psychomotor and focal motor attacks .
|
-
- HY-14836
-
|
JZP 4
|
Calcium Channel
Sodium Channel
|
Neurological Disease
|
|
Elpetrigine (JZP 4) is a potent calcium and sodium channel blocker. Elpetrigine has anticonvulsant, antidepressant, antimania and anxiolytic effects. Elpetrigine can be used in the research of epilepsy and bipolar disorder .
|
-
- HY-W142701
-
|
|
Drug Derivative
|
Others
|
|
Succinamide is an amide derivative of succinic acid. Succinamide is the parent compound of some anticonvulsant drugs, proteins, plastic adhesives. Succinamide can be used in biochemical experiments and in the synthesis of other compounds .
|
-
- HY-B1642S
-
|
Peganone-d5
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Ethotoin-d5 is the deuterium labeled Ethotoin . Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin .
|
-
- HY-W722128
-
-
- HY-108964
-
-
- HY-W587570
-
|
|
Drug Metabolite
|
Metabolic Disease
|
|
(S) -4-Hydroxy mephenytoin is a metabolite derived from the stereoselective metabolism of mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate.
|
-
- HY-107702
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects .
|
-
- HY-168363
-
|
WE-973
|
GABA Receptor
|
Neurological Disease
|
|
Ciclotizolam (WE-973) is a thienotriazolodiazepine with anticonvulsant and anti-aggressive activities. Ciclotizolam binds to benzodiazepine receptors in the central nervous system. Ciclotizolam decreases total sleep time in cats .
|
-
- HY-122400
-
|
Spirodon
|
Drug Derivative
|
Neurological Disease
|
|
Tetrantoin is a spirocyclic hydantoin and anticonvulsant with an approximate ED50 of 54 mg/kg.Tetrantoin inhibits and prevents convulsions induced by maximum electric shock test.Tetrantoin can be used for the research of epilepsy .
|
-
- HY-101708
-
-
- HY-125508
-
|
|
GABA Receptor
|
Neurological Disease
|
|
CCD-3693 is an orally active GABA receptor agonist. CCD-3693 has anxiolytic, anticonvulsant and sedative hypnotic activities and can be used in research related to neurological diseases .
|
-
- HY-B1642R
-
|
Peganone (Standard)
|
Calcium Channel
Reference Standards
|
Neurological Disease
|
|
Ethotoin (Standard) is the analytical standard of Ethotoin. This product is intended for research and analytical applications. Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin .
|
-
- HY-152732
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B1657A
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
-
- HY-100782
-
|
2-APH; 2-Amino-7-phosphonoheptanoic acid
|
iGluR
|
Neurological Disease
|
|
DL-AP7 is a competitive NMDA antagonist and an anticonvulsant. DL-AP7 blocks the NMDA-induced convulsions and impairs learning performance in a passive avoidance task in mice .
|
-
- HY-B1184S3
-
-
- HY-152755
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Cyanouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-114880
-
|
|
Cannabinoid Receptor
|
Neurological Disease
|
|
AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (Ki= 0.9 nM), exhibiting anticonvulsant activity .
|
-
- HY-W020098
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-C-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-15068R
-
|
FG9202 (Standard)
|
iGluR
Reference Standards
|
Neurological Disease
|
|
NBQX (Standard) is the analytical standard of NBQX. This product is intended for research and analytical applications. NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
|
-
- HY-114703S
-
-
- HY-108506R
-
|
BIA 2-005 (Standard); GP 47779 (Standard)
|
Reference Standards
Sodium Channel
|
Neurological Disease
|
|
Licarbazepine (Standard) is the analytical standard of Licarbazepine. This product is intended for research and analytical applications. Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
- HY-107323A
-
|
QM 6008 hydrochloride; Thiadipone hydrochloride; Tiadipone hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
Bentazepam (QM 6008, Thiadipone) hydrocholide is a compound with short-action anxiolytic effect. Bentazepam hydrocholide shows anticonvulsant and sedative properties. Bentazepam hydrocholide can be used for the research of depressive disorder and anxiety .
|
-
- HY-103536
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galnon is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon exhibits anticonvulsant and anxiolytic effects .
|
-
- HY-108506S2
-
-
- HY-B2124
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
10,11-Dihydrocarbamazepine is the active metabolite of Oxcarbazepine. 10,11-Dihydrocarbamazepine also is an intermediate. Oxcarbazepine is rapidly and almost completely converted to 10,11-Dihydrocarbamazepine with probable Anticonvulsant efficacy .
|
-
- HY-152764
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-α-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-A0042
-
|
CGP 33101; E 2080; RUF 331
|
Sodium Channel
|
Neurological Disease
|
|
Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-152777
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152299
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(t-Butyloxycarbonylmethoxy)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-113320
-
|
5β-Androsterone
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Etiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity . Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the GABAA receptor than its enantiomer form .
|
-
- HY-119105
-
|
|
GABA Receptor
|
Neurological Disease
|
|
LY81067, a diaryltriazine, effectively protects against Pentylenetetrazole- and Picrotoxin-induced convulsions in mice. LY81067 exerts its anticonvulsant effects by binding to or near Picrotoxin (HY-101391) binding sites .
|
-
- HY-154735
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Allyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B1730
-
|
|
Cyclic GMP-AMP Synthase
|
Neurological Disease
Metabolic Disease
|
|
Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
|
-
- HY-152388
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-beta-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-120769
-
-
- HY-152665
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(β-D-Xylofuranosyl)uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-15356
-
-
- HY-103536A
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galnon TFA is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon TFA exhibits anticonvulsant and anxiolytic effects .
|
-
- HY-119716
-
|
|
|
Neurological Disease
|
|
Cyheptamide is an orally active anticonvulsant and antiepileptic agent. Cyheptamide exhibits moderate acute toxicity in animal models, with lethal doses varying by species specificity. Cyheptamide can be used in studies related to convulsions and epilepsy .
|
-
- HY-14953R
-
|
AWD 131-138 (Standard)
|
GABA Receptor
Reference Standards
|
Neurological Disease
|
|
Imepitoin (Standard) is the analytical standard of Imepitoin. This product is intended for research and analytical applications. Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.
|
-
- HY-132155
-
|
NSC 91508
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Indan-5-sulphonamide (Compd 1) is a carbonic anhydrase inhibitor and anticonvulsant agent, with Ki values of 0.039 nM (hCA XII), 6.5 nM (hCA XIV) and 5.1 nM (hCA XIV), respectively .
|
-
- HY-B0339
-
-
- HY-152970
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Others
|
|
7'-O-DMT-morpholino uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-147982
-
|
|
GABA Receptor
|
Neurological Disease
|
|
GABA-AT-IN-1 (Compound 6) is a γ-aminobutyric acid aminotransferase (GABA-AT) inhibitor and significantly elevates the mouse brain GABA level. GABA-AT-IN-1 has the ability to cross the BBB and can be used as an anticonvulsant .
|
-
- HY-149077
-
|
|
Others
|
Others
|
|
2′-Deoxy-5-methoxyuridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W012481R
-
|
Ethylphenylhydantoin (Standard); Phenylethyihydantoin (Standard); Desmethylmephenytoin (Standard)
|
Drug Metabolite
Reference Standards
|
Neurological Disease
|
|
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
- HY-W845607
-
|
|
Monoamine Oxidase
|
Neurological Disease
|
|
Milacemide, a glycinamide derivative, is an orally active MAO-B inhibitor with anticonvulsant activity. Milacemide reduces the levels of dihydroxyphenylacetic acid and homovanilic acid, but increases the levels of dopamine and serotonin in the caudate nucleus. Milacemide is promising for research of Alzheimer's disease .
|
-
- HY-154734
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-(4-Nitrobenzyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W557556
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',5'-Bis-O-(triphenylMethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-105296
-
|
|
Sigma Receptor
mAChR
|
Cancer
|
|
Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome .
|
-
- HY-152677
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-(2-Methoxy)ethyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-181828
-
|
|
iGluR
Dopamine Receptor
|
Neurological Disease
|
|
SePP is a blood-brain barrier-permeable NMDAR antagonist and dopamine/norepinephrine reuptake inhibitor, with a Ki of 28.7 nM for rat NMDAR. SePP exerts anticonvulsant effects. SePP can be used in research related to fragile X syndrome .
|
-
- HY-B0184S1
-
|
Felbamyl-d5; Felbatol-d5; Taloxa-d5
|
iGluR
|
Neurological Disease
|
|
Felbamate-d5 is the deuterium labeled Felbamate . Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
|
-
- HY-B0114
-
|
GP 47680
|
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-W012481
-
|
Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin
|
Drug Metabolite
|
Neurological Disease
|
|
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
- HY-119146
-
|
CI-716 free base
|
Drug Derivative
|
Neurological Disease
|
|
Zolazepam (CI-716 free base) is a benzodiazepine derivative with anxiolytic and anticonvulsant properties. Zolazepam combined with Tiletamine causes a decrease in ventilation, resulting in the development of respiratory acidosis. Zolazepam can be used as sedative and muscle relaxants .
|
-
- HY-154217
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′,5′-Bis-O-(triphenylmethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B0184R
-
|
W-554 (Standard); ADD-03055 (Standard)
|
Reference Standards
iGluR
|
Neurological Disease
|
|
Felbamate (Standard) is the analytical standard of Felbamate. This product is intended for research and analytical applications. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
- HY-182548
-
|
|
GABA Receptor
Sodium Channel
iGluR
|
Cardiovascular Disease
Neurological Disease
|
|
BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABAA receptor (GABAA receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na + channels (Ki = 350 μM) and NMDA receptors (NMDA receptor) (IC50 = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine .
|
-
- HY-B0211AR
-
|
PK 26124 hydrochloride (Standard)
|
Sodium Channel
GABA Receptor
Reference Standards
|
Neurological Disease
Cancer
|
|
Riluzole hydrochloride (Standard) is the analytical standard of Riluzole hydrochloride. This product is intended for research and analytical applications. Riluzole hydrochloride is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.
|
-
- HY-W197533
-
|
|
GABA Receptor
|
Neurological Disease
|
|
3-Hydroxymethyl-β-carboline antagonizes the anxiolytic and anticonvulsant actions of Diazepam and reverses the sedative action of Flurazepam. 3-Hydroxymethyl-β-carboline also antagonizes the cerebrovascular and cerebral metabolic depression produced by Flurazepam .
|
-
- HY-108707
-
|
|
iGluR
|
Neurological Disease
|
|
LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
|
-
- HY-154285
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(2-Methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W094475E
-
|
Epsom salts (Pharmaceutical primary standard, USP)
|
Drug Derivative
|
Neurological Disease
Metabolic Disease
|
|
Magnesium sulfate heptahydrate, United States Pharmacopeia (USP) Reference Standard (Epsom salts (Pharmaceutical primary standard, USP)) is currently the anticonvulsant of choice for the prevention and control of eclamptic fits and is also widely used as a tocolytic agent .
|
-
- HY-P1132
-
-
- HY-152529
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-5-methoxyuridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-114871
-
|
|
GABA Receptor
|
Neurological Disease
|
|
SL651498 is a full agonist of α2 and α3 GABAA receptors, and a partial agonist of α1 and α5 GABAA receptors. SL651498 shows anxiolytic and anticonvulsant activities .
|
-
- HY-152522
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-4’-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B0211R
-
|
PK 26124 (Standard)
|
Reference Standards
Sodium Channel
GABA Receptor
|
Neurological Disease
Cancer
|
|
Riluzole (Standard) is the analytical standard of Riluzole. This product is intended for research and analytical applications. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na + channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.
|
-
- HY-107694
-
|
(Rac)-MK-801
|
iGluR
|
Others
|
|
(Rac)-Dizocilpine ((Rac)-MK-801) is the racemate of Dizocilpine (HY-15084B). Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist .
|
-
- HY-117162
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs .
|
-
- HY-120524
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 31358 is an anticonvulsant agent that binds to a site on the NMDA receptor complex that is coupled to both the transmitter recognition site and to the channel domain. CGP 31358 inhibits the binding of L-Glutamate to the NMDA receptor complex with an IC50 of 53 μM .
|
-
- HY-W010513
-
|
|
Endogenous Metabolite
Bacterial
|
Neurological Disease
|
|
3-Methylvaleric Acid is a branched alkanoic acid. 3-Methylvaleric Acid can be utilized by Pseudomonas citronettotis as a sole carbon source for its growth. 3-Methylvaleric Acid derivatives exhibit anti-hyperalgesic and anticonvulsant activities .
|
-
- HY-154738
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-[3-(tert-Butoxycarbonyl)amino]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152783
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyl-5-fluorouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152969
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-103230R
-
|
|
Reference Standards
iGluR
|
Neurological Disease
|
|
IEM-1460 (Standard) is the analytical standard of IEM-1460 (HY-103230). This product is intended for research and analytical applications. IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo .
|
-
- HY-P1132A
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect .
|
-
- HY-101240R
-
|
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
|
Propranolol glycol (Standard) is the analytical standard of Propranolol glycol. This product is intended for research and analytical applications. Propranolol glycol is a metabolite of propranolol (HY-B0573B). Propranolol glycol shows instantaneous anticonvulsant activity .
|
-
- HY-152779
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-5’(R)-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-105693
-
|
|
iGluR
|
Neurological Disease
|
|
Fluorofelbamate, a Felbamate (HY-B0184) analog, is a potent NMDA receptor antagonist. Fluorofelbamate exhibits anticonvulsant and antiepileptogenic effects in an experimental rat model of self-sustaining status epilepticus (SSSE). Fluorofelbamate can be used for epilepsy research .
|
-
- HY-15068AR
-
|
FG9202 disodium (Standard)
|
iGluR
Reference Standards
|
Neurological Disease
|
|
NBQX (disodium) (Standard) is the analytical standard of NBQX (disodium). This product is intended for research and analytical applications. NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
|
-
- HY-101207
-
|
|
GABA Receptor
|
Neurological Disease
|
|
NCS-382 is a potent GABA receptor antagonist and also a GHBR receptor antagonist. NCS-382 has anticonvulsant and antisedative activity. NCS-382 is used in the related research of hereditary nervous system diseases .
|
-
- HY-B0184S
-
|
|
iGluR
|
Neurological Disease
|
|
Felbamate-d4 (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
- HY-152358
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Methyl-2’-O-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-P1285
-
|
Con-R
|
iGluR
|
Neurological Disease
|
|
Conantokin R (Con-R) is an NMDA receptor peptide antagonist with an IC50 of 93 nM. Conantokin R binds Zn 2+ and Mg 2+ with Kds of 0.15 μM and 6.5 μM, respectively. Conantokin R shows anticonvulsant activity .
|
-
- HY-108506S4
-
-
- HY-130205
-
|
CP 1552 S
|
Monoamine Oxidase
|
Neurological Disease
|
|
Milacemide hydrochloride (CP 1552 S), a glycinamide derivative, is an orally active MAO-B inhibitor with anticonvulsant activity. Milacemide hydrochloride reduces the levels of dihydroxyphenylacetic acid and homovanilic acid, but increases the levels of dopamine and serotonin in the caudate nucleus. Milacemide hydrochloride is promising for research of Alzheimer's disease .
|
-
- HY-152798
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-2’-β-C-methyl uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154737
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-[(Pyrid-4-yl)methyl]uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B0211S1
-
-
- HY-A0092
-
|
3,5,5,-Trimethyloxazolidine-2,4-dione
|
Calcium Channel
|
Neurological Disease
|
|
Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
|
-
- HY-107695
-
|
FPL 12924AA
|
iGluR
Sodium Channel
|
Neurological Disease
|
|
Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na + channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively . Remacemide hydrochloride is an anticonvulsant agent .
|
-
- HY-N9502
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
Linalool oxide is a monoterpene and found in aromatic plant essential oils and is a secondary metabolite in elongating wheat plants. Linalool oxide has antinociceptive, anticonvulsant, and anxiolytic activity. Linalool oxide can be used for the research of pain, epilepsy, anxiety disorders .
|
-
- HY-152681
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-[(Tetrahydro-2-furanyl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152463
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′-C-2-Propen-1-yluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-146099
-
|
|
GABA Receptor
|
Neurological Disease
|
|
GABAA receptor agent 7 (compoud 5c) is a potent GABAA receptor positive modulator. GABAA receptor agent 7 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 7 has the potential for the research of epilepsy .
|
-
- HY-114489B
-
|
|
Apoptosis
Influenza Virus
Parasite
|
Infection
Neurological Disease
Cancer
|
|
Haemanthamine hydrochloride is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine hydrochloride targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation. Haemanthamine hydrochloride has pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities .
|
-
- HY-B0495A
-
|
LTG hydrate; BW430C hydrate
|
Sodium Channel
Autophagy
|
Neurological Disease
Cancer
|
|
Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-106885
-
|
|
Drug Derivative
|
Neurological Disease
|
|
F 2692 is an orally effective derivative of pyridazine. F 2692 has significant anti anxiety effects. F 2692 also has activities such as anticonvulsant, sedative, and muscle relaxant. F 2692 can be used for research on neurological disorders such as anxiety disorders .
|
-
- HY-114489A
-
|
|
Apoptosis
Influenza Virus
Parasite
|
Infection
Neurological Disease
Cancer
|
|
Haemanthamine is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation. Haemanthamine has pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities .
|
-
- HY-165514
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Nafimidone is a stable and brain-penetrant antiepileptic compound Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. However, The effective window of Nafimidone is narrow, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .
|
-
- HY-146100
-
|
|
GABA Receptor
|
Neurological Disease
|
|
GABAA receptor agent 8 (compoud 5e) is a potent GABAA receptor positive modulator. GABAA receptor agent 8 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 8 has the potential for the research of epilepsy .
|
-
- HY-103505
-
|
|
GABA Receptor
|
Neurological Disease
|
|
CL 218872 is an orally active and selective ligand for the benzodiazepine receptor subtype BZ1. CL 218872 exhibits anxiolytic, sedative and anticonvulsant activities. CL 218872 can be used in researches of anxiety related disorders and epilepsy .
|
-
- HY-165514A
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Nafimidone is a stable and brain-penetrant antiepileptic compound. Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. Nafimidone exhibits the narrow effective window, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .
|
-
- HY-152683
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-[(Pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-129105
-
|
|
GABA Receptor
Cytochrome P450
|
Neurological Disease
|
|
Chlormethiazole is an potent and orally active GABAA agonist . Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus .
|
-
- HY-152574
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Amino-2’-deoxy-2’-O-methyluridine hydrochloride is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-113320S
-
|
5β-Androsterone-d5
|
Isotope-Labeled Compounds
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Etiocholanolone-d5 is the deuterium labeled Etiocholanolone. Etiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity . Etiocholanolone is a less potent?neurosteroid positive allosteric modulator?(PAM) of the GABAA?receptor than its?enantiomer form .
|
-
- HY-177986
-
|
|
Drug Derivative
|
Neurological Disease
|
|
NCR 631 is a 3-HAO inhibitor and 3-hydroxyanthranilic acid (HY-W001171) analogue. NCR-631 has anticonvulsant properties. NCR-631shows a concentration-dependent protective effect against the anoxia .
|
-
- HY-152674
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Deoxy-2′-fluoro-5-methoxy-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-A0296
-
|
Clomethiazole hydrochloride
|
Cytochrome P450
|
Neurological Disease
|
|
Clomethiazole hydrochloride is a potent and orally active GABAA agonist . Clomethiazole hydrochloride inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes. Clomethiazole hydrochloride is an anticonvulsant agent and has the potential for treating convulsive status epilepticus .
|
-
- HY-B1657AS
-
|
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Fosphenytoin-d10 (disodium) is deuterium labeled Fosphenytoin (disodium). Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
-
- HY-136591
-
|
|
Drug Metabolite
|
Neurological Disease
Cancer
|
|
Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [ 3H]tryptophan binding to rat hepatic nuclei .
|
-
- HY-154560
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-acetyl-N3-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B1427
-
|
Gamma-amino-beta-hydroxybutyric acid
|
Drug Derivative
|
Neurological Disease
|
|
Gamibetal (Gamma-amino-beta-hydroxybutyric acid) is γ-amino-β-hydroxybutyric acid (GABOB), a hydroxylated derivative of GABA (γ-aminobutyric acid). Gamibetal exhibits central inhibitory and anticonvulsant activities. Gamibetal can be used in research on epilepsy, neuralgia, and other conditions .
|
-
- HY-114542
-
|
|
Drug Derivative
|
Others
|
|
LY 201409 is an anticonvulsant compound that is an analog of LY-201116 (HY-114705) with improved metabolic activity. LY 201409 antagonizes maximal electroconvulsive-induced seizures, has mixed effects on seizures induced by multiple chemoconvulsants, and affects behavior and sleep in mice .
|
-
- HY-B1229
-
|
3-Methylbutanamide
|
GABA Receptor
|
Neurological Disease
Metabolic Disease
|
|
Isovaleramide (3-Methylbutanamide) is an orally active anticonvulsant. Isovaleramide inhibits alcohol dehydrogenase (ADH) activity and regulates GABAergic system. Isovaleramide reduces acute kidney injury. Isovaleramide has antiepileptic, anxiolytic, sedative and hypnotic effects[1] .
|
-
- HY-154466
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-107703
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity . CGP 39551 shows measurable inhibitory activity at both L-[ 3H]-glutamate (Ki=8.4 μM) .
|
-
- HY-B0339S
-
-
- HY-P1932
-
-
- HY-B0211S
-
|
PK 26124-13C,15N2
|
GABA Receptor
Sodium Channel
|
Neurological Disease
|
|
Riluzole- 13C, 15N2 is the 13C and 15N labeled Riluzole . Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM .
|
-
- HY-15084B
-
Dizocilpine
Maximum Cited Publications
44 Publications Verification
MK-801
|
iGluR
|
Neurological Disease
|
|
Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux .
|
-
- HY-48973
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Others
|
|
2'-Fluoro-2'-deoxy-ara-U-3'-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-123193
-
|
Pro-diazepam
|
Drug Intermediate
|
Neurological Disease
|
|
Avizafone (Pro-diazepam), a pro-drug of Diazepam, is an anticonvulsant agent. Avizafone can be used as an antidote of nerve agent poisoning. In vivo, Avizafone is rapidly hydrolyzed by aminopeptidase to produce lysine and diazepam. Avizafone has research areas including neurological disease, such as epilepsy .
|
-
- HY-113320S1
-
|
5β-Androsterone-d2
|
Isotope-Labeled Compounds
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Etiocholanolone-d2 is the deuterium labeled Etiocholanolone. Etiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity . Etiocholanolone is a less potent?neurosteroid positive allosteric modulator?(PAM) of the GABAA?receptor than its?enantiomer form .
|
-
- HY-12503R
-
|
|
iGluR
|
Neurological Disease
Cancer
|
|
CFM-2 (Standard) is the analytical standard of CFM-2. This product is intended for research and analytical applications. CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .
|
-
- HY-108504R
-
|
V 102862 (Standard)
|
Reference Standards
Sodium Channel
|
Neurological Disease
|
|
Co 102862 (Standard) is the analytical standard of Co 102862 (HY-108504). This product is intended for research and analytical applications. Co 102862 (V 102862) is a potent, broad-spectrum, state-dependent Na+ channel blocker. Co 102862 is also an orally active anticonvulsant .
|
-
- HY-161896
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Transcription factor-IN-1 (Compound 4e) is an inhibitor for transcription factor. Transcription factor-IN-1 exhibits anticonvulsant activity by antagonism with pentylenetetrazole (PTZ) (ED50 =34.5 mg/kg). Transcription factor-IN-1 exhibits antidepressant effects in rat models .
|
-
- HY-B0696A
-
|
NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696B
-
|
NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; TGB hydrochloride hydrate
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (NO050328; NO328; TGB) hydrochloride hydrate is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride hydrate exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride hydrate is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696
-
|
NO050328; NO328; TGB
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-152363
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Methyl-2’-O-(2-methoxyethyl)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-107515
-
|
|
mGluR
|
Neurological Disease
|
|
LY367385 is a highly selective and potent mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects .
|
-
- HY-160604
-
|
FPL 12924; PR 934-423; FPL 13592
|
iGluR
|
Neurological Disease
|
|
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research .
|
-
- HY-16579
-
|
HOE 36-801 hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents .
|
-
- HY-154173
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(t-Butyldimethylsilyl)-2’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-118974
-
|
|
Calcium Channel
|
Neurological Disease
Cancer
|
|
PD-151307 is an N-type calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC50 of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .
|
-
- HY-105498
-
|
|
Sodium Channel
|
Neurological Disease
|
|
ADD-196022 is an orally active antiepileptic and anticonvulsant agent. ADD-196022 shows ED50 values of 26.2 mg/kg and 5.79 mg/kg for intraperitoneal injection in mice and orally administration in rats. ADD-196022 can be used for the research of neurological disease .
|
-
- HY-B0495
-
|
LTG; BW430C
|
Sodium Channel
Autophagy
|
Neurological Disease
Cancer
|
|
Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-13993B
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 25-6981 hydrochloride is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 hydrochloride shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 hydrochloride has the potential for the research of parkinson's disease (PD) .
|
-
- HY-154813
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′,5′-Di-O-acetyl-2′-deoxy-2′-fluorouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-N8303
-
|
|
ERK
PAK
|
Neurological Disease
Inflammation/Immunology
|
|
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .
|
-
- HY-W094475D
-
|
Epsom salts, meets analytical specification of Ph. Eur. BP USP FCC
|
Drug Derivative
|
Neurological Disease
Metabolic Disease
|
|
Magnesium sulfate heptahydrate, meets analytical specification of Ph. Eur. BP USP FCC (Epsom salts, meets analytical specification of Ph. Eur. BP USP FCC) is currently the anticonvulsant of choice for the prevention and control of eclamptic fits and is also widely used as a tocolytic agent .
|
-
- HY-154358
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-alpha-C-Allyl-2’,3’-bis(O-t-butyldimethylsilyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-49199
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-(t-butyldimethylsilyl)-4'-C-hydroxymethyl uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-Y1267
-
-
- HY-147377
-
-
- HY-154488
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-O-[(1,1-Dimethylethyl)dimethylsilyl]-2′-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-16579A
-
|
HOE 36-801
|
GABA Receptor
|
Neurological Disease
|
|
Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
|
-
- HY-13993
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .
|
-
- HY-U00199A
-
|
(S)-N-Desmethyl zopiclone; SEP-174559
|
GABA Receptor
nAChR
iGluR
|
Neurological Disease
|
|
(S)-Norzopiclone ((S)-N-Desmethyl zopiclone; SEP-174559) is a metabolite of Zopiclone with anxiolytic and anticonvulsant effects. (S)-Norzopiclone has benzodiazepine-like actions at γ2-bearing subtypes of the GABAA receptor and inhibits nACh and NMDA receptors .
|
-
- HY-107515A
-
|
|
mGluR
|
Neurological Disease
|
|
LY367385 hydrochloride is a highly selective and potent mGluR1a antagonist. LY367385 hydrochloride has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 hydrochloride has neuroprotective, anticonvulsant and antiepileptic effects .
|
-
- HY-106437
-
|
|
GABA Receptor
|
Neurological Disease
|
|
ELB-139 is a progesterone analogue. ELB-139 is a GABAA receptor partial agonist. ELB-139 has anxiolytic and anticonvulsant activity. ELB-139 induces increase of extracellular 5-HT in the striatum and the medial prefrontal cortex of rats .
|
-
- HY-B0114S1
-
-
- HY-B1657AR
-
|
|
Reference Standards
Sodium Channel
|
Neurological Disease
|
|
Fosphenytoin (disodium) (Standard) is the analytical standard of Fosphenytoin (disodium). This product is intended for research and analytical applications. Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
-
- HY-B1730R
-
|
|
Cyclic GMP-AMP Synthase
Reference Standards
|
Neurological Disease
Metabolic Disease
|
|
Phensuximide (Standard) is the analytical standard of Phensuximide. This product is intended for research and analytical applications. Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
|
-
- HY-13993A
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .
|
-
- HY-154410
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-DMT-2’-deoxy-2’-fluoro-β-D-arabinouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-134337
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5'-O-DMTr-3'-O-methyl uridine-3'-CED-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-B1283
-
|
|
iGluR
|
Neurological Disease
|
|
Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .
|
-
- HY-158252S
-
|
NO050328-d5 hydrochloride; NO328-d5 hydrochloride; TGB-d5 hydrochloride
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-103234
-
|
|
iGluR
|
Neurological Disease
|
|
GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .
|
-
- HY-152691
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-125928
-
|
|
Sodium Channel
|
Neurological Disease
|
|
AA43279 is an in gamma-aminobutyric acid (GABA) fast-firing interneurons located activator for Nav1.1 channel (SCN1A) with an EC50 of 9.5 μM. AA43279 enhances specific neuronal firing activity in vitro, and exhibits anticonvulsant activity in rat MEST model .
|
-
- HY-W013378S
-
|
|
Endogenous Metabolite
Isotope-Labeled Compounds
|
Others
|
|
Carbamazepine 10,11 epoxide-d2 is the deuterium labeled Carbamazepine 10,11 epoxide . Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
|
-
- HY-103234B
-
|
|
iGluR
|
Neurological Disease
|
|
GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .
|
-
- HY-W017851
-
|
|
Drug Intermediate
|
Neurological Disease
|
|
4-Phenyl-2-pyrrolidinone is a precursor and synthetic intermediate. 4-Phenyl-2-pyrrolidinone can be used as a precursor in the synthesis of compounds with anticonvulsant and nootropic activities and is an intermediate in the synthesis of bromodomain-containing protein 4 (BRD4) bromodomain 1 inhibitors .
|
-
- HY-B0339R
-
-
- HY-B0246
-
-
- HY-103234A
-
|
|
iGluR
|
Neurological Disease
|
|
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
|
-
- HY-W131122
-
|
|
Bacterial
|
Others
|
|
1,3,4-Oxadiazoles are a class of synthetic compounds with important medicinal value, which show a variety of biological activities such as anticonvulsant, antidepressant, analgesic, anti-inflammatory, antiallergic, antipsychotic, antimicrobial, antituberculous, antitumor, and antiviral. 1,3,4-Oxadiazole derivatives need to be further developed .
|
-
- HY-154492
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-4’,5’-didehydro-5’-deoxyuridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-114883
-
|
L-Homocarnosine
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-103392
-
|
BCX2600
|
Cytochrome P450
|
Neurological Disease
|
|
Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively.
|
-
- HY-B0162
-
|
|
HCN Channel
|
Cardiovascular Disease
Cancer
|
|
Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-169651
-
|
|
GABA Receptor
|
Neurological Disease
|
|
GABA-IN-4 (Compound 17) is a N-(indol-3-ylglyoxylyl)benzylamine derivative. GABA-IN-4 exhibits high affinity for the benzodiazepine receptor (BzR) (binding site in GABAA receptor complex) with Ki value of 67 nM. Benzodiazepines are widely used as antianxiety, sedative-hypnotic and anticonvulsant agents .
|
-
- HY-110032
-
|
LTG isethionate; BW430C isethionate
|
Sodium Channel
Autophagy
|
Neurological Disease
Cancer
|
|
Lamotrigine (BW430C) isethionate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine isethionate selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine isethionate can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-B0114R
-
|
GP 47680 (Standard)
|
Reference Standards
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine (Standard) is the analytical standard of Oxcarbazepine. This product is intended for research and analytical applications. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-107701
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 hydrochloride acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity .
|
-
- HY-B2117
-
|
|
Epoxide Hydrolase
EBV
|
Infection
Neurological Disease
|
|
Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .
|
-
- HY-B0162A
-
|
|
HCN Channel
|
Cardiovascular Disease
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-115685
-
|
|
GABA Receptor
|
Neurological Disease
|
|
3-Methyl-GABA is a potent GABA aminotransferase activator. 3-Methyl-GABA can fit the binding pocket of GABAA receptor (GABAaR). 3-Methyl-GABA can activate L-glutamic acid decarboxylase (GAD). 3-Methyl-GABA has anticonvulsant activity .
|
-
- HY-154175
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-[6-(Diethoxyphosphinyl)-2-O-(2-methoxyethyl)-β-D-ribo-hexofuranosyl]uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W702001
-
|
Pro-diazepam dihydrobromide
|
Drug Intermediate
|
Neurological Disease
|
|
Avizafone (Pro-diazepam) dihydrobromide, a pro-drug of Diazepam, is an anticonvulsant agent. Avizafone dihydrobromide can be used as an antidote of nerve agent poisoning. In vivo, Avizafone dihydrobromide is rapidly hydrolyzed by aminopeptidase to produce lysine and diazepam. Avizafone dihydrobromide has research areas including neurological disease, such as epilepsy .
|
-
- HY-100547
-
|
|
iGluR
|
Neurological Disease
|
|
IEM-1754, a dicationic adamantane derivative, is a potent blocker of open channels of native ionotropic glutamate receptors including quisqualate-sensitive receptors in insect muscles, NMDAR in cultured rat cortical neurons, and AMPAR in freshly isolated hippocampal cells. IEM-1754 shows anticonvulsant potency in vivo .
|
-
- HY-114883A
-
|
L-Homocarnosine TFA
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-152792
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-179215A
-
|
|
GABA Receptor
|
Neurological Disease
|
|
OV329 is a potent GABA aminotransferase inactivator. OV329 is a Vigabatrin (HY-15399) analogue. OV329 can increase brain GABA levels and block abnormal intracerebral hyperexcitability. OV329 exhibits anticonvulsant and antiepileptic activities. OV329 can be used for the research of neurological disease, such as seizure .
|
-
- HY-177302
-
|
|
mGluR
|
Neurological Disease
|
|
mGluR2 modulator 6 (Compound 25-a) is a mGluR2 modulator. mGluR2 modulator 6 has anticonvulsant activity in the 6Hz epilepsy model, and the effect is better when combined with Levetiracetam (HY-B0106). mGluR2 modulator 6 can be used in the research of epilepsy .
|
-
- HY-179215
-
|
|
GABA Receptor
|
Neurological Disease
|
|
OV329 hydrochloride is a potent GABA aminotransferase inactivator. OV329 hydrochloride is a Vigabatrin (HY-15399) analogue. OV329 hydrochloride can increase brain GABA levels and block abnormal intracerebral hyperexcitability. OV329 hydrochloride exhibits anticonvulsant and antiepileptic activities. OV329 hydrochloride can be used for the research of neurological disease, such as seizure .
|
-
- HY-154552
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-benzoyl-3’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-108964R
-
|
|
Reference Standards
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Carvone (Standard) is the analytical standard of Carvone. This product is intended for research and analytical applications. Carvone is a ketone monoterpene found mostly in the essential oils from plants of the genus Mentha. Carvone is widely used in the pharmaceutical industry, cosmetics and agriculture. Carvone has such effects as antimicrobial, antioxidant, anti-inflammatory, antispasmodic, antinociceptive, anticonvulsant .
|
-
- HY-B0114S3
-
|
GP 47680-d10
|
Isotope-Labeled Compounds
Apoptosis
Sodium Channel
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-18663B
-
|
|
iGluR
|
Neurological Disease
|
|
CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
|
-
- HY-18663
-
|
|
iGluR
|
Neurological Disease
|
|
CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
|
-
- HY-B0114S
-
|
GP 47680-d4
|
Isotope-Labeled Compounds
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-Y1267D
-
-
- HY-18663A
-
|
|
iGluR
|
Neurological Disease
|
|
CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
|
-
- HY-123335A
-
|
|
Somatostatin Receptor
|
Neurological Disease
|
|
L-796778 acetate is a selective agonist of the sst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 acetate is a partial agonist that inhibits Forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM. L-796778 acetate has anticonvulsant effect .
|
-
- HY-N0219
-
Bicuculline
Maximum Cited Publications
37 Publications Verification
(+)-Bicuculline
|
GABA Receptor
|
Neurological Disease
|
|
Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABAA receptor antagonist (IC50=2 μM). Bicuculline also blocks Ca 2+ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .
|
-
- HY-B0114S2
-
|
GP 47680-d8
|
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects .
|
-
- HY-105296R
-
|
|
Reference Standards
Sigma Receptor
mAChR
|
Cancer
|
|
Blarcamesine (Standard) is the analytical standard of Blarcamesine (HY-105296). This product is intended for research and analytical applications. Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome .
|
-
- HY-B0162B
-
|
|
HCN Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Ivabradine sulfate is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine sulfate reduces dose-dependently heart rate without modification of blood pressure. Ivabradine sulfate shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-107701A
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 78608 is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). CGP 78608 has anticonvulsant activities .
|
-
- HY-B1122
-
|
(S)-Cycloserine; (S)-4-Amino-3-isoxazolidone
|
GABA Receptor
HIV
|
Neurological Disease
Cancer
|
|
L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains .
|
-
- HY-W010589
-
|
H-Abu-OH
|
Endogenous Metabolite
Drug Intermediate
|
Metabolic Disease
|
|
L-2-Aminobutyric acid (H-Abu-OH) is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
|
-
- HY-154517
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Cyanoethyl-5’-O-(4,4’-dimethoxytrityl)-2’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-A0042R
-
|
CGP 33101 (Standard); E 2080 (Standard); RUF 331 (Standard)
|
Sodium Channel
Reference Standards
|
Neurological Disease
|
|
Rufinamide (Standard) is the analytical standard of Rufinamide (HY-A0042). This product is intended for research and analytical applications. Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-154647
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-(2S)-[2-(tert-Butoxycarbonyl)amino-3-(tert-butoxy carbonyl)]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-133195
-
|
Fenazoxine
|
Sodium Channel
|
Neurological Disease
|
|
Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 μM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups .
|
-
- HY-B0696S1
-
|
NO050328-d4; NO328-d4; TGB-d4
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696S
-
|
NO050328-d6; NO328-d6; TGB-d6
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696AS
-
|
NO050328-d4 hydrochloride; NO328-d4 hydrochloride; TGB-d4 hydrochloride
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696AR
-
|
NO050328 hydrochloride (Standard); NO328 hydrochloride (Standard); TGB hydrochloride (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (hydrochloride) (Standard) is the analytical standard of Tiagabine (hydrochloride). This product is intended for research and analytical applications. Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-154582
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Naphthyl-beta-methylaminocarbony-3’-O-acetyl-2’-O-methyl-5’-O-DMTr-uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-A0092R
-
|
3,5,5,-Trimethyloxazolidine-2,4-dione (Standard)
|
Reference Standards
Calcium Channel
|
Neurological Disease
|
|
Trimethadione (Standard) is the analytical standard of Trimethadione. This product is intended for research and analytical applications. Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
|
-
- HY-136591R
-
|
|
Drug Metabolite
Reference Standards
|
Neurological Disease
Cancer
|
|
Demoxepam (Standard) is the analytical standard of Demoxepam. This product is intended for research and analytical applications. Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [ 3H]tryptophan binding to rat hepatic nuclei .
|
-
- HY-103536AR
-
|
|
Reference Standards
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galnon TFA (Standard) is the analytical standard of Galnon TFA (HY-103536A). This product is intended for research and analytical applications. Galnon TFA is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon TFA exhibits anticonvulsant and anxiolytic effects .
|
-
- HY-B2124R
-
|
|
Reference Standards
Drug Metabolite
|
Neurological Disease
|
|
10,11-Dihydrocarbamazepine (Standard) is the analytical standard of 10,11-Dihydrocarbamazepine. This product is intended for research and analytical applications. 10,11-Dihydrocarbamazepine is the active metabolite of Oxcarbazepine. 10,11-Dihydrocarbamazepine also is an intermediate. Oxcarbazepine is rapidly and almost completely converted to 10,11-Dihydrocarbamazepine with probable Anticonvulsant efficacy .
|
-
- HY-16579AS2
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
|
-
- HY-129105R
-
|
|
GABA Receptor
Cytochrome P450
Reference Standards
|
Neurological Disease
|
|
Clomethiazole (Standard) is the analytical standard of Clomethiazole. This product is intended for research and analytical applications. Chlormethiazole is an potent and orally active GABAA agonist . Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus .
|
-
- HY-B0495S5
-
|
LTG-d3; BW430C-d3
|
Autophagy
Sodium Channel
|
Neurological Disease
|
|
Lamotrigine-d3 is the deuterium labeled Lamotrigine . Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-N16538
-
|
|
Drug Derivative
|
Cardiovascular Disease
Neurological Disease
|
|
4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .
|
-
- HY-128772
-
|
|
Sodium Channel
|
Neurological Disease
|
|
XPC-6444 is a highly potent, isoform-selective, and CNS-penetrant NaV1.6 inhibitor (IC50=41 nM for hNaV1.6). XPC-6444 also displays potent block of NaV1.2 (IC50=125 nM). XPC-6444 shows anticonvulsant activity .
|
-
- HY-B0495S4
-
|
LTG-13C3; BW430C-13C3
|
Sodium Channel
Autophagy
|
Neurological Disease
|
|
Lamotrigine- 13C3 is the 13C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-103509
-
|
|
GABA Receptor
|
Neurological Disease
|
|
NNC 05-2090 hydrochloride is a GABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC50< /sub>: 10.6 μM). NNC 05-2090 hydrochloride also inhibits mGAT2 with a Ki value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .
|
-
- HY-A0042S
-
|
CGP 33101-d2; E 2080-d2; RUF 331-d2
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-B0495S7
-
|
LTG-13C; BW430C-13C
|
Isotope-Labeled Compounds
|
Neurological Disease
Cancer
|
|
Lamotrigine- 13C (LTG- 13C) is 13C labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
- HY-B1199A
-
|
|
Monoamine Oxidase
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Nialamide hydrochloride is a non-selective monoamine oxidase (MAO) inhibitor. Nialamide hydrochloride inhibits MAO and regulates ROS production. Nialamide hydrochloride induces hyperkinesis in animals, enhances the anticonvulsant effect of Diphenylhydantoin in mice, increases rectal temperature, and enhances the pressor effect of Norepinephrine. Nialamide hydrochloride can be used in the research of depression, inflammatory diseases, neurodegenerative diseases, and hypertension .
|
-
- HY-120146
-
|
|
GABA Receptor
|
Neurological Disease
|
|
NNC 05-2090 is aGABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC50 sub>: 10.6 μM). NNC 05-2090 also inhibits mGAT2 with a Ki value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .
|
-
- HY-164728
-
|
|
Calcium Channel
|
Neurological Disease
|
|
Pregabalin diacid is an impurity of Pregabalin, a lipophilic GABA (γ-aminobutyric acid) analog with anxiolytic and anticonvulsant activity. Pregabalin may act on the α(2)β subunit of voltage-dependent calcium channels, which are widely distributed in the peripheral and central nervous systems. Pregabalin can effectively induce hypoalgesia and improve behavioral disorders .
|
-
- HY-108707R
-
|
|
Reference Standards
iGluR
|
Neurological Disease
|
|
LY3130481 (Standard) is the analytical standard of LY3130481 (HY-108707). This product is intended for research and analytical applications. LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
|
-
- HY-W012481S
-
|
Ethylphenylhydantoin-d5; Phenylethyihydantoin-d5; Desmethylmephenytoin-d5
|
Isotope-Labeled Compounds
Drug Metabolite
|
Neurological Disease
|
|
Nirvanol-d5 (Ethylphenylhydantoin-d5) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
- HY-B1199
-
-
- HY-14336
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
SB 271046 is a potent, selective, orally active and BBB-permeable 5-HT6 receptor antagonist with a pKi of 8.92-9.09. SB 271046 show >200-fold selective for the 5-HT6 receptor over other receptors, binding sites and ion channels. SB 271046 has anticonvulsant activity .
|
-
- HY-123193S
-
|
Pro-diazepam-d5 dihydrobromide
|
Isotope-Labeled Compounds
Drug Intermediate
|
Neurological Disease
|
|
Avizafone-d5 dihydrobromide is the deuterium labeled Avizafone dihydrobromide . Avizafone (Pro-diazepam) dihydrobromide, a pro-drug of Diazepam, is an anticonvulsant agent. Avizafone dihydrobromide can be used as an antidote of nerve agent poisoning. In vivo, Avizafone is rapidly hydrolyzed by aminopeptidase to produce lysine and diazepam. Avizafone dihydrobromide has research areas including neurological disease, such as epilepsy.
|
-
- HY-B1283S
-
|
|
Isotope-Labeled Compounds
iGluR
|
Neurological Disease
|
|
Mephenesin-d3 is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .
|
-
- HY-B0495R
-
|
LTG (Standard); BW430C (Standard)
|
Reference Standards
Sodium Channel
|
Neurological Disease
|
|
Lamotrigine (Standard) is the analytical standard of Lamotrigine. This product is intended for research and analytical applications. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-W708332
-
|
|
Isotope-Labeled Compounds
Bacterial
Endogenous Metabolite
|
Neurological Disease
|
|
3-Methylvaleric acid-d11 is the deuterium labeled 3-Methylvaleric Acid (HY-W010513). 3-Methylvaleric Acid is a branched alkanoic acid. 3-Methylvaleric Acid can be utilized by Pseudomonas citronettotis as a sole carbon source for its growth. 3-Methylvaleric Acid derivatives exhibit anti-hyperalgesic and anticonvulsant activities .
|
-
- HY-122114
-
|
|
Potassium Channel
|
Neurological Disease
|
|
ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC50 of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects .
|
-
- HY-16579AR
-
|
HOE 36-801 (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Etifoxine (Standard) is the analytical standard of Etifoxine. This product is intended for research and analytical applications. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
|
-
- HY-16579R
-
|
HOE 36-801 hydrochloride (Standard)
|
GABA Receptor
Reference Standards
|
Neurological Disease
|
|
Etifoxine (hydrochloride) (Standard) is the analytical standard of Etifoxine (hydrochloride). This product is intended for research and analytical applications. Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents .
|
-
- HY-172816
-
|
|
Carbonic Anhydrase
mTOR
NKCC
|
Neurological Disease
|
|
Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels .
|
-
- HY-121141
-
|
|
nAChR
|
Neurological Disease
|
|
Adiphenine is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine has anticonvulsant effects .
|
-
- HY-103505R
-
|
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
CL 218872 (Standard) is the analytical standard of CL 218872 (HY-103505). This product is intended for research and analytical applications. CL 218872 is an orally active and selective ligand for the benzodiazepine receptor subtype BZ1. CL 218872 exhibits anxiolytic, sedative and anticonvulsant activities. CL 218872 can be used in researches of anxiety related disorders and epilepsy .
|
-
- HY-B0162S
-
|
|
Isotope-Labeled Compounds
HCN Channel
|
Cardiovascular Disease
|
|
Ivabradine-d6 is the deuterium labeled Ivabradine . Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-105115
-
|
ZK 112119
|
GABA Receptor
|
Neurological Disease
|
|
Abecarnil (ZK 112119) is a ligand or a partial agonist for benzodiazepine (BZ) receptor. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil can act as a positive allosteric modulator of GABAA receptor. Abecarnil inhibits the binding of the BZ [3H]lormetazepam to rat cerebral cortex membranes, with an IC50 of 0.82 nM. Abecarnil can be used for epilepsy research .
|
-
- HY-103392S
-
|
|
Isotope-Labeled Compounds
Cytochrome P450
|
Neurological Disease
|
|
Stiripentol-d9 is the deuterium labeled Stiripentol. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Kis of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively .
|
-
- HY-B0379A
-
|
|
nAChR
|
Neurological Disease
|
|
Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects .
|
-
- HY-B0246R
-
|
CBZ (Standard); NSC 169864 (Standard)
|
Reference Standards
Sodium Channel
Autophagy
Mitophagy
Potassium Channel
Calcium Channel
HDAC
|
Neurological Disease
Cancer
|
|
Carbamazepine (Standard) is the analytical standard of Carbamazepine. This product is intended for research and analytical applications. Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na +, Ca 2+, and K + channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain .
|
-
- HY-B0688S
-
|
4,4′-Diaminodiphenyl sulfone-d8; DDS-d8
|
Antibiotic
Parasite
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
Inflammation/Immunology
Cancer
|
|
Dapsone-d8 is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide antibiotic with antibacterial, antigenic and anti-inflammatory activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone can be used as an anticonvulsant and also in the research of skin and glioblastoma diseases .
|
-
- HY-B0495S1
-
|
LTG-13C,d3; BW430C-13C,d3
|
Isotope-Labeled Compounds
Sodium Channel
Autophagy
|
Neurological Disease
|
|
Lamotrigine- 13C,d3 is the 13C- and deuterium labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
- HY-B1803
-
|
ICI 136753
|
GABA Receptor
|
Neurological Disease
|
|
Tracazolate (ICI 136753) is an orally active non-benzodiazepine anxiolytic. Tracazolate significantly enhances the binding of the radioligand 3H-flunitrazepam ( 3H-FLU) to brain tissue benzodiazepine receptors. Tracazolate enhances the binding of γ-aminobutyric acid (GABA) to its receptors. Tracazolate exhibits anticonvulsant activity. Tracazolate can be used in anxiety-related research .
|
-
- HY-W010513R
-
|
|
Reference Standards
Biochemical Assay Reagents
|
Others
|
|
3-Methylvaleric acid (Standard) is an analytical standard form of 3-Methylvaleric acid (HY-W010513). This product is intended for research and analytical applications. 3-Methylvaleric Acid is a branched alkanoic acid. 3-Methylvaleric Acid can be utilized by Pseudomonas citronettotis as a sole carbon source for its growth. 3-Methylvaleric Acid derivatives exhibit anti-hyperalgesic and anticonvulsant activities .
|
-
- HY-B0162AR
-
|
|
Reference Standards
HCN Channel
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Ivabradine hydrochloride (Standard) is the analytical standard of Ivabradine hydrochloride. This product is intended for research and analytical applications. Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
- HY-100840
-
|
(S)-4-Carboxy-3-hydroxyphenylglycine
|
mGluR
|
Neurological Disease
|
|
(S)-4C3HPG ((S)-4-Carboxy-3-hydroxyphenylglycine) is an antagonist of metabotropic glutamate receptor 1a (mGluR 1a) and an agonist of GluR2. (S)-4C3HPG has the anticonvulsant activity and protects against audiogenic seizures in DBA/2 mice .
|
-
- HY-114975
-
|
|
iGluR
|
Neurological Disease
|
|
EGIS-8332 is a non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and Quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC50 = 5.1-9.0 μM). EGIS-8332 exhibits anticonvulsant and neuroprotective effects. EGIS-8332 can be used for the research of neurological disease .
|
-
- HY-Y0729
-
|
|
Tyrosinase
Bacterial
Fungal
Drug Derivative
|
Infection
Neurological Disease
|
|
4-Chlorocinnamic acid is a derivative of Cinnamic acid (HY-N0610A). 4-Chlorocinnamic acid inhibits the monophenolase and diphenolase activities of mushroom tyrosinase with IC50 values of 0.477 mM and 0.229 mM, respectively. 4-Chlorocinnamic acid inhibits the mycelial growth of Colletotrichum gloeosporioides. 4-Chlorocinnamic acid exhibits anticonvulsant activity against acute epilepsy induced by pentylenetetrazol .
|
-
- HY-181874
-
|
|
Potassium Channel
|
Neurological Disease
|
|
E0714 is a blood-brain barrier-permeable, selective Kv7.2 potassium channel activator, with EC50 values of 1.90 μM and 0.021 μM for homotetrameric Kv7.2 channels and heterotetrameric Kv7.2/7.3 channels, respectively. E0714 exhibits anticonvulsant activity. E0714 can be used in research related to epilepsy .
|
-
- HY-B0495S3
-
|
|
Autophagy
Sodium Channel
|
Neurological Disease
|
|
Lamotrigine- 13C2, 15N is the 13C and 15N labeled Lamotrigine . Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-N9502R
-
|
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
|
Linalool oxide (Standard) is the analytical standard of Linalool oxide (HY-N9502). This product is intended for research and analytical applications. Linalool oxide is a monoterpene and found in aromatic plant essential oils and is a secondary metabolite in elongating wheat plants. Linalool oxide has antinociceptive, anticonvulsant, and anxiolytic activity. Linalool oxide can be used for the research of pain, epilepsy, anxiety disorders .
|
-
- HY-148792
-
|
PRAX-562
|
Sodium Channel
|
Neurological Disease
|
|
Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel. Relutrigine potently and preferentially inhibits persistent INa induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC50 values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity .
|
-
- HY-103234AR
-
|
|
Reference Standards
iGluR
|
Neurological Disease
|
|
GYKI 52466 (dihydrochloride) (Standard) is the analytical standard of GYKI 52466 (dihydrochloride). This product is intended for research and analytical applications. GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
|
-
- HY-118207
-
|
|
GABA Receptor
|
Cancer
|
|
LU-32-176B, a GABA transporter 1(GAT1) selective inhibitor, is found to exert a synergistic anticonvulsant action with GAT2 transport inhibitor EF1502. LU-32-176B inhibits neurons, astrocytes and mGAT1 with the IC50 values of 2μM, 1μM, 4μM, respectively .
|
-
- HY-154652
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-2,4(1H,3H)-pyrimidinedione is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-P10698
-
|
|
Peptide-Drug Conjugates (PDCs)
LDLR
|
Neurological Disease
|
|
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
|
-
- HY-152476
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-C-Ethynyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-β-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-103504R
-
|
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
(S)-SNAP5114 (Standard) is the analytical standard of (S)-SNAP5114 (HY-103504). This product is intended for research and analytical applications. (S)-SNAP5114 is a selective GABA transport inhibitor, with IC50 values of 5 μM and 21 μM for hGAT-3 and rGAT-2, respectively. (S)-SNAP5114 is an anticonvulsant agent .
|
-
- HY-N0219R
-
|
(+)-Bicuculline (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Bicuculline (Standard) is the analytical standard of Bicuculline. This product is intended for research and analytical applications. Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABAA receptor antagonist (IC50=2 μM). Bicuculline also blocks Ca2+ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .
|
-
- HY-105056
-
|
Ro 16-6028
|
GABA Receptor
|
Neurological Disease
|
|
Bretazenil (Ro 16-6028) is a partial agonist at the gamma-aminobutyric acid A (GABAA) receptor-linked benzodiazepine site. Bretazenil is potent benzodiazepine examined, exhibiting an IC50 (concentration at which half-maximal inhibition of specific [35S]TBPS binding occurs) of 6.1 nM. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2. Anticonvulsant effects .
|
-
- HY-B0246S4
-
|
CBZ-d4; NSC 169864-d4
|
Isotope-Labeled Compounds
|
Others
|
|
Carbamazepine-d4 (CBZ-d4) is the deuterium labeled Carbamazepine (HY-B0246) . Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na +, Ca 2+, and K + channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.
|
-
- HY-107515AR
-
|
|
Reference Standards
mGluR
|
Neurological Disease
|
|
LY367385 hydrochloride (Standard) is the analytical standard of LY367385 (hydrochloride) (HY-107515A). This product is intended for research and analytical applications. LY367385 hydrochloride is a highly selective and potent mGluR1a antagonist. LY367385 hydrochloride has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 hydrochloride has neuroprotective, anticonvulsant and antiepileptic effects .
|
-
- HY-W644305
-
|
3β-Androstenol
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
Androst-16-en-3-ol is a pheromone derived from boars that triggers mating responses in estrous sows. It also exists in human urine, plasma, saliva and sweat. As an endogenous neurosteroid, Androst-16-en-3-ol acts as a positive allosteric modulator of GABAA receptors (GABAA receptor) and exerts anxiolytic, antidepressant and anticonvulsant activities in mice.
|
-
- HY-B2117R
-
|
|
Reference Standards
Epoxide Hydrolase
EBV
|
Infection
Neurological Disease
|
|
Valpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .
|
-
- HY-B1606
-
|
Chlorthymol; 6-Chlorothymol
|
Environmental Pollutants
Bacterial
AP-1
GABA Receptor
|
Infection
Neurological Disease
|
|
Chlothymol is a potent positive modulator of the GABAA receptor subunit LGC-37, anticonvulsant, and antibacterial agent. Chlothymol inhibits Pentylenetetrazol-induced c-fos expression. Chlothymol inhibits the growth of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) strains, including LAC, with an MIC of 32 μg/mL. Chlorothymol has protective effects against epileptic seizures in various mouse models .
|
-
- HY-103392R
-
|
BCX2600 (Standard)
|
Reference Standards
Cytochrome P450
|
Neurological Disease
|
|
Stiripentol (Standard) is the analytical standard of Stiripentol (HY-103392). This product is intended for research and analytical applications. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively.
|
-
- HY-B0495S
-
|
LTG-13C3,d3; BW430C-13C3,d3
|
Isotope-Labeled Compounds
Sodium Channel
Autophagy
|
Neurological Disease
|
|
Lamotrigine- 13C3,d3 is the 13C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
- HY-B1122R
-
|
(S)-Cycloserine (Standard); (S)-4-Amino-3-isoxazolidone (Standard)
|
Reference Standards
GABA Receptor
HIV
|
Neurological Disease
Cancer
|
|
L-Cycloserine (Standard) is the analytical standard of L-Cycloserine. This product is intended for research and analytical applications. L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains[1][2][3][4].
|
-
- HY-A0042S1
-
|
CGP 33101-15N,d2; E 2080-15N,d2; RUF 331-15N,d2
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Rufinamide- 15N,d2 (CGP 33101- 15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-105857
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Thiazesim is a benzothiazepine compound with a thiophene structure and acts as a GABAA receptor inhibitor, exerting anticonvulsant and antidepressant effects. Thiazesim exhibits specific pharmacological properties in animal experiments. Thiazesim reduces motor activity in rats and effectively inhibits rat killing responses, with a ratio of 2.1 between the ED50 in rotarod tests and the ED50 for anti-killing behavior. Thiazesim can be widely used in basic and clinical studies related to epilepsy .
|
-
- HY-105857A
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Thiazesim hydrochloride is a benzothiazepine compound with a thiophene structure and acts as a GABAA receptor inhibitor, exerting anticonvulsant and antidepressant effects. Thiazesim hydrochloride exhibits specific pharmacological properties in animal experiments. Thiazesim hydrochloride reduces motor activity in rats and effectively inhibits rat killing responses, with a ratio of 2.1 between the ED50 in rotarod tests and the ED50 for anti-killing behavior. Thiazesim hydrochloride can be widely used in basic and clinical studies related to epilepsy .
|
-
- HY-101440A
-
|
CHF-3381
|
iGluR
Monoamine Oxidase
|
Neurological Disease
|
|
Indantadol hydrochloride (CHF-3381) is an orally active, non-selective NMDA antagonist and MAO inhibitor. Indantadol hydrochloride blocks the binding of [³H]-MK-801 to NMDA receptors in a non-competitive manner, with an IC50 of 8.1 μM. Indantadol hydrochloride completely inhibits dopamine release caused by NMDA. Indantadol hydrochloride protects neurons, with an ED₅₀ of 35 μM. Indantadol hydrochloride has anticonvulsant and anti-high pain hypersensitivity activities .
|
-
- HY-B0495S8
-
|
LTG-13C7,15N; BW430C-13C7,15N
|
Isotope-Labeled Compounds
Autophagy
Sodium Channel
|
Neurological Disease
Cancer
|
|
Lamotrigine- 13C7, 15N (LTG- 13C7, 15N) is 13C and 15N labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
- HY-12596
-
|
|
Calcium Channel
Sodium Channel
Potassium Channel
|
Neurological Disease
|
|
JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na + channels and N-type Ca 2+ channels, and is effective as a K + channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC50=35 μM) and CA-I (18 μM) .
|
-
- HY-A0042S2
-
|
CGP 33101-15N,d2-1; E 2080-15N,d2-1; RUF 331-15N,d2-1
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Rufinamide- 15N,d2-1 (CGP 33101- 15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-W010589S2
-
|
H-Abu-OH-d6
|
Isotope-Labeled Compounds
Endogenous Metabolite
Drug Intermediate
|
Metabolic Disease
|
|
L-2-Aminobutyric acid-d6 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
|
-
- HY-P3960
-
|
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS .
|
-
- HY-D0803
-
|
|
Apoptosis
VEGFR
PI3K
Akt
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
- HY-W010589S
-
|
H-Abu-OH-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
Drug Intermediate
|
Metabolic Disease
|
|
L-2-Aminobutyric acid-d3 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
|
-
- HY-19259
-
|
|
Adenosine Kinase
|
Neurological Disease
|
|
GP3269 is a selective and orally active human adenosine kinase (AK) inhibitor with an IC50 of 11 nM against human adenosine kinase. GP3269 increases adenosine levels at epileptic foci, activates A1 receptors on excitatory neurons, and exhibits anticonvulsant activity in rats. GP3269 does not induce hemodynamic effects including changes in blood pressure or heart rate in rats. GP3269 can be used for epilepsy-related research .
|
-
- HY-111751
-
|
|
iGluR
|
Neurological Disease
|
|
JNJ-61432059 is a blood-brain barrier-permeable, orally active TARP γ-8-associated AMPAR modulator with anticonvulsant activity. JNJ-61432059 negatively regulates GluA1 and positively modulates GluA2-containing AMPARs. JNJ-61432059 exerts potent protective effects in rodent epilepsy models. JNJ-61432059 is applicable for epilepsy-related research .
|
-
- HY-101440
-
|
CHF-3381 free base
|
iGluR
Monoamine Oxidase
|
Neurological Disease
|
|
Indantadol (the free base of CHF-3381) is an orally active, non-selective NMDA antagonist and MAO inhibitor. Indantadol blocks the binding of [³H]-MK-801 to NMDA receptors in a non-competitive manner, with an IC50 of 8.1 μM. Indantadol completely inhibits dopamine release caused by NMDA. Indantadol protects neurons, with an ED₅₀ of 35 μM. Indantadol has anticonvulsant and anti-high pain hypersensitivity activities .
|
-
- HY-118758
-
|
γ-Kainic acid-glutamic acid
|
Sodium Channel
|
Neurological Disease
|
|
γ-Kainylglutamic acid (γ-Kainic acid-glutamic acid), a dipeptide derived from kainic and L-Glutamic acids, is a selective antagonist of amino acid induced neuroexcitation with anticonvulsant properties. γ-Kainylglutamic acid inhibits the stimulation of Na + fluxes induced in brain slices by the neuroexcitant N-methyl-D-aspartic acid. γ-Kainylglutamic acid is also effective in protecting mice from picrotoxin-induced convulsions with an EC50 value of 0.17 μmol .
|
-
- HY-118018
-
|
|
GABA Receptor
|
Neurological Disease
|
|
CHF-2993 is an orally active anticonvulsant. CHF-2993 antagonizes Bicuculline (HY-N0219)- and Picrotoxin (HY-101391)-induced tonic convulsions in mice, shows no activity against Pentylenetetrazole-induced clonic convulsions in mice, and partially reduces Veratridine (HY-N6691)-induced aspartate efflux in rat cortical synaptosomes. CHF-2993 can be used in the research of epilepsy .
|
-
- HY-W011235
-
|
|
5-HT Receptor
Calcium Channel
Drug Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity .
|
-
- HY-101087
-
|
|
Carbonic Anhydrase
Amyloid-β
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
|
-
- HY-108327
-
|
|
Potassium Channel
|
Neurological Disease
|
|
PF-05020182 is an orally active opener for Kv7 channel, that activates human Kv7.2/7.3, Kv7.4 and Kv7.3/7.5 with EC50 of 334, 625 and 588 nM, respectively. PF-05020182 exhibits anticonvulsant activity in rats corneal electric shock-induced tonic seizure (MES) models. PF-05020182 is blood-brain barrier (BBB) penetrable .
|
-
- HY-14336A
-
|
SB 271046A
|
5-HT Receptor
|
Neurological Disease
|
|
SB 271046 Hydrochloride (SB 271046A) is a potent, selective, orally active and BBB-permeable 5-HT6 receptor antagonist with pKi of 9.02, 8.55, and 8.81 for rat, pig and human, respectively. SB 271046 Hydrochloride is over 200 fold selective for the 5-HT6 receptor vs 55 other receptors, binding sites and ion channels. Anticonvulsant activity (EC50=0.16 μM) .
|
-
- HY-B0379AR
-
|
|
Reference Standards
nAChR
|
Neurological Disease
|
|
Adiphenine (hydrochloride) (Standard) is the analytical standard of Adiphenine (hydrochloride). This product is intended for research and analytical applications. Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects .
|
-
- HY-N6778
-
|
|
Potassium Channel
Calcium Channel
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
Paxilline is an indole alkaloid mycotoxin derived from Penicillium paxilli, which effectively inhibits the BK channel through a channel-blocking mechanism. Paxilline also inhibits sarco/endoplasmic reticulum Ca 2+-stimulated ATPase (SERCA), with IC50 values ranging from 5 μM to 50 μM for different SERCA isoforms. Paxilline exhibits significant anticonvulsant and neuroprotective effects, as well as certain antioxidant activity .
|
-
- HY-154736
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-(Butyn-3-yl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . N3-(Butyn-3-yl)uridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B0495S6
-
|
LTG-13C2,15N2,d3; BW430C-13C2,15N2,d3
|
Autophagy
Sodium Channel
Isotope-Labeled Compounds
|
Neurological Disease
Cancer
|
|
Lamotrigine- 13C2, 15N2,d3 is 15N and deuterated labeled Lamotrigine (HY-B0495). Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-134004
-
|
Carbetapentane
|
Sigma Receptor
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Pentoxyverine (Carbetapentane) is an orally active sigma-1 receptor agonist, with Kis of 41 nM, 894 nM and 75 nM for σ1, σ2 and guinea-pig brain membran σ1, respectively. Pentoxyverine is a muscarinic antagonist. Pentoxyverine is a potent antitussive, anticonvulsant, and spasmolytic agent. Pentoxyverine can be used for inhibiting bronchial interceptor, weakening of cough reflex, bronchial smooth muscle relaxation and reduction of airway resistance .
|
-
- HY-W010589R
-
|
H-Abu-OH (Standard)
|
Reference Standards
Endogenous Metabolite
Drug Intermediate
|
Metabolic Disease
|
|
L-2-Aminobutyric acid (Standard) is the analytical standard of L-2-Aminobutyric acid. This product is intended for research and analytical applications. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
|
-
- HY-148135
-
|
|
Carbonic Anhydrase
|
Neurological Disease
|
|
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and >50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
|
-
- HY-103534
-
|
|
GABA Receptor
|
Neurological Disease
|
|
CI-966 hydrochloride is a potent, selective, orally active and brain-penetrant inhibitor of the GABA transporter GAT-1, with IC50s of 0.26 μM and 1.2 μM for hGAT-1, rGAT-1, respectively. CI-966 hydrochloride shows more than 200-fold selectivity over GAT-2, GAT-3, and BGT-3. CI-966 hydrochloride exhibits anticonvulsant and neuroprotective activities .
|
-
- HY-W013378S2
-
|
|
Endogenous Metabolite
|
Others
|
|
Carbamazepine 10,11-epoxide- 13C,d2 is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a 13C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
|
-
- HY-W013507
-
-
- HY-W550494
-
|
|
Others
|
Neurological Disease
|
|
1-(Pyridin-4-yl)heptan-1-one (Compound R=n-C₆H₁₃) is an anticonvulsant agent. 1-(Pyridin-4-yl)heptan-1-one can protect mice from electroshock-induced convulsions. 1-(Pyridin-4-yl)heptan-1-one is promising for research of convulsion-related diseases such as epilepsy .
|
-
- HY-17549
-
|
CRL 40028
|
Adrenergic Receptor
|
Neurological Disease
|
|
Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
|
-
- HY-I0746
-
|
m-Aminobenzoic acid; 3ABA
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
|
-
- HY-123240
-
|
|
GABA Receptor
|
Neurological Disease
|
|
CI-966 is a potent, selective, orally active and brain-penetrant inhibitor of the GABA transporter GAT-1, with IC50s of 0.26 μM and 1.2 μM for hGAT-1, rGAT-1, respectively. CI-966 shows more than 200-fold selectivity over GAT-2, GAT-3, and BGT-3. CI-966 exhibits anticonvulsant and neuroprotective activities .
|
-
- HY-17032
-
|
(rac)-AS1069562 free base; YM-08054 free base
|
Endogenous Metabolite
|
Neurological Disease
|
|
Indeloxazine ((rac)-AS1069562 free base) is a brain active compound with anti-amnesic activity. Indeloxazine significantly prolonged the step latency in senescence accelerated mice (SAM-P/8/Ta), indicating that it has a promoting effect on brain function. Indeloxazine has a broader pharmacology than piracetam and exhibits stronger anti-amnesic activity. Indeloxazine has also been used as an anticonvulsant compound, further supporting its potential use in neuroprotection and behavioral improvement .
|
-
- HY-103509R
-
|
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
NNC 05-2090 hydrochloride (Standard) is the analytical standard of NNC 05-2090 hydrochloride (HY-103509). This product is intended for research and analytical applications. NNC 05-2090 hydrochloride is a GABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC50< /sub>: 10.6 μM). NNC 05-2090 hydrochloride also inhibits mGAT2 with a Ki value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .
|
-
- HY-19130
-
|
|
Adenosine Receptor
|
Neurological Disease
|
|
BW-534U87 is an orally active adenosine A1 receptor agonist and competitive adenosine deaminase (ADA) inhibitor (Ki=7 μM). BW-534U87 elevates brain adenosine levels and suppresses epileptiform activity. BW-534U87 demonstrate anticonvulsant efficacy in animal seizure models. BW-534U87 is promising for research of epilepsy and adenosine-related neuropsychiatric disorders .
|
-
- HY-105056R
-
|
Ro 16-6028 (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Bretazenil (Standard) is the analytical standard of Bretazenil (HY-105056). This product is intended for research and analytical applications. Bretazenil (Ro 16-6028) is a partial agonist at the gamma-aminobutyric acid A (GABAA) receptor-linked benzodiazepine site. Bretazenil is potent benzodiazepine examined, exhibiting an IC50 (concentration at which half-maximal inhibition of specific [35S]TBPS binding occurs) of 6.1 nM. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2. Anticonvulsant effects .
|
-
- HY-118424
-
|
|
iGluR
|
Neurological Disease
Metabolic Disease
|
|
JNJ-55511118 is a selective TARP γ-8 binding AMPA receptor modulator with oral bioavailability and blood-brain barrier permeability, with a Ki of 26 nM. JNJ-55511118 reduces voluntary intake of sweetened alcohol in male mice. In rodent models, JNJ-55511118 inhibits hippocampal neurotransmission, reduces specific electroencephalogram frequency bands, induces transient hyperlocomotion, impairs learning and memory abilities, and exerts anticonvulsant effects. JNJ-55511118 is applicable to research related to alcohol use disorder and seizures .
|
-
- HY-77650
-
|
4'-Azidouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4'-C-azidouridine (4'-Azidouridine) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4'-C-Azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-103506
-
|
NO-711 hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
NNC-711 (NO-711 hydrochloride) is a potent and selective inhibitor of GAT-1 (GABA transporter 1) with IC50 values of 0.04, 0.38, 171, 1700, 349, 622 μM for human GAT-1, rat GAT-1, rGAT-2, hGAT-3, rGAT-3, hBGT-3, respectively. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity .
|
-
- HY-B1803A
-
|
ICI 136753 hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
Tracazolate (ICI 136753) hydrochloride is a potent GABAA receptor modulator. Tracazolate hydrochloride has selectivity for β3 and potentiates α1β1γ2s (EC50=13.2 μM), α1β3γ2 (EC50=1.5 μM). Tracazolate hydrochloride has the potency (EC50) determined by the nature of the third subunit (γ1-3, δ, ε) within the receptor complex. Tracazolate hydrochloride possesses anxiolytic and anticonvulsant activity .
|
-
- HY-B1055
-
|
Carbetapentane citrate
|
Sigma Receptor
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Pentoxyverine (Carbetapentane) citrate is an orally active and blood-brain barrier permeability sigma-1 receptor agonist, with Kis of 41 nM, 894 nM and 75 nM for σ1, σ2 and guinea-pig brain membrane σ1, respectively. Pentoxyverine citrate is a muscarinic antagonist. Pentoxyverine citrate is a potent antitussive, anticonvulsant, and spasmolytic agent. Pentoxyverine citrate can be used for inhibiting bronchial interceptor, weakening of cough reflex, bronchial smooth muscle relaxation and reduction of airway resistance .
|
-
- HY-B0237
-
|
DL-Aminoglutethimide
|
Cytochrome P450
|
Neurological Disease
Endocrinology
Cancer
|
|
Aminoglutethimide (DL-Aminoglutethimide) is an orally active anticonvulsant with various endocrine-related side effects. Aminoglutethimide blocks multiple steroid hormone synthesis pathways by inhibiting several cytochrome P-450-dependent hydroxylases, such as aromatase, cholesterol side-chain cleavage enzyme, 11-hydroxylase, and 18-hydroxylase, with IC50 values of 0.3, 3.5, 120, and 20 μM, respectively. Aminoglutethimide reduces cortisol levels. Aminoglutethimide can be used in research on Cushing's syndrome, breast cancer, and other conditions .
|
-
- HY-168773
-
|
|
EAAT
|
Neurological Disease
|
|
(R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .
|
-
- HY-D0803R
-
|
|
Reference Standards
Apoptosis
VEGFR
PI3K
Akt
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Thymoquinone (Standard) is the analytical standard of Thymoquinone. This product is intended for research and analytical applications. Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
- HY-W001692
-
|
DOV 273547
|
GABA Receptor
|
Neurological Disease
|
|
Ocinaplon (DOV 273547) is an orally active positive allosteric modulator of GABAA receptor, with an EC50 ranging from 3.07 μM (α1β2γ2 subtype) to 10.03 μM (α1β2γ3 subtype). Ocinaplon enhances GABA-stimulated chloride currents across multiple GABAA receptor subtypes, with varying potency between different subtypes. Ocinaplon exerts anxiolytic and anticonvulsant effects, and causes motor impairment at high doses. Ocinaplon can be used for research on generalized anxiety disorder .
|
-
- HY-134004R
-
|
Carbetapentane (Standard)
|
Reference Standards
Sigma Receptor
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Pentoxyverine (Standard) is the analytical standard of Pentoxyverine. This product is intended for research and analytical applications. Pentoxyverine (Carbetapentane) is an orally active sigma-1 receptor agonist, with Kis of 41 nM, 894 nM and 75 nM for σ1, σ2 and guinea-pig brain membran σ1, respectively. Pentoxyverine is a muscarinic antagonist. Pentoxyverine is a potent antitussive, anticonvulsant, and spasmolytic agent. Pentoxyverine can be used for inhibiting bronchial interceptor, weakening of cough reflex, bronchial smooth muscle relaxation and reduction of airway resistance .
|
-
- HY-19021
-
|
|
mGluR
|
Neurological Disease
|
|
ADD-17014 is a L-Glu antagonist. ADD-17014 impairs presynaptic excitatory amino acid L-Glu neurotransmission. ADD-17014 is a prodrug of its β-amino alcohol metabolite, and the metabolite acts as a NMDA receptor antagonist by binding to the MK-801 site located inside the NMDA receptor or ion channel. ADD-17014 has an anticonvulsant and anti-ischemic activity. ADD-17014 can be used for neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease and stroke research .
|
-
- HY-14336AR
-
|
SB 271046A (Standard)
|
5-HT Receptor
Reference Standards
|
Neurological Disease
|
|
SB 271046 (Hydrochloride) (Standard) is the analytical standard of SB 271046 (Hydrochloride). This product is intended for research and analytical applications. SB 271046 Hydrochloride (SB 271046A) is a potent, selective, orally active and BBB-permeable 5-HT6 receptor antagonist with pKi of 9.02, 8.55, and 8.81 for rat, pig and human, respectively. SB 271046 Hydrochloride is over 200 fold selective for the 5-HT6 receptor vs 55 other receptors, binding sites and ion channels. Anticonvulsant activity (EC50=0.16 μM) .
|
-
- HY-W677042
-
|
5α-Androst-16-en-3α-ol
|
GABA Receptor
|
Neurological Disease
|
|
α-Androstenol (5α-Androst-16-en-3α-ol) is a steroid pheromone that has been found in boar testes and male axillary sweat. α-Androstenol is also a positive allosteric modulator of GABAA receptors, which enhances GABA-activated currents in primary mouse cerebellar granule cells (EC50 of 0.4 μM). α-Androstenol produces anxiolytic-like, antidepressant-like, and anticonvulsant effects in mice. α-Androstenol can be used for the research of seizures .
|
-
- HY-101087R
-
|
|
Reference Standards
Carbonic Anhydrase
Amyloid-β
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide (HY-101087). This product is intended for research and analytical applications. Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
|
-
- HY-180056
-
|
|
Carbonic Anhydrase
NKCC
mTOR
|
Neurological Disease
|
|
CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .
|
-
- HY-152985
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-Azido-3’-deoxy-4-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-B1302
-
|
|
P-glycoprotein
PARP
Caspase
Apoptosis
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on IK(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .
|
-
- HY-W013507R
-
|
|
Reference Standards
NF-κB
Reactive Oxygen Species (ROS)
Glutathione Peroxidase
Phytohormone
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
(rac)-Methyl jasmonate (Standard) is the analytical standard of Methyl jasmonate. This product is intended for research and analytical applications. (rac)-Methyl jasmonate is the racemate of Methyl jasmonate (HY-135663). Methyl jasmonate is a phytohormone that regulates the defense response of plants under biotic and biotic stress through jasmonate signaling pathway. Methyl jasmonate inhibits the activation of NF-κB signaling pathway. Methyl jasmonate can promote the mitochondrial ROS production, but also scavenges free radicals and reduces the oxidative stress. Methyl jasmonate exhibits anti-inflammatory, antitumor, anticonvulsant, antinociceptive and sedative activities .
|
-
- HY-I0746R
-
|
m-Aminobenzoic acid (Standard); 3ABA (Standard)
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
|
-
- HY-103566R
-
|
|
Reference Standards
mGluR
EGFR
p38 MAPK
Apoptosis
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
LY456236 (Standard) is the analytical standard of LY456236 (HY-103566). This product is intended for research and analytical applications. LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 has anticonvulsant effects and blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research .
|
-
- HY-N1516R
-
|
|
Reference Standards
Apoptosis
|
Cancer
|
|
3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
|
-
- HY-W115674
-
|
|
P-glycoprotein
PARP
Caspase
Apoptosis
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Quinidine hydrochloride is an orally active antiarrhythmic agent. Quinidine hydrochloride reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride exerts sustained block and open-channel block effects on IK(f). Quinidine hydrochloride alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride can be used in studies related to uterine sarcoma and seizures .
|
-
- HY-B1055R
-
|
Carbetapentane citrate (Standard)
|
Reference Standards
Sigma Receptor
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Pentoxyverine (citrate) (Standard) is the analytical standard of Pentoxyverine (citrate). This product is intended for research and analytical applications. Pentoxyverine (Carbetapentane) citrate is an orally active sigma-1 receptor agonist, with Kis of 41 nM, 894 nM and 75 nM for σ1, σ2 and guinea-pig brain membrane σ1, respectively. Pentoxyverine citrate is a muscarinic antagonist. Pentoxyverine citrate is a potent antitussive, anticonvulsant, and spasmolytic agent. Pentoxyverine citrate can be used for inhibiting bronchial interceptor, weakening of cough reflex, bronchial smooth muscle relaxation and reduction of airway resistance [4].
|
-
- HY-W008344
-
|
|
Nucleoside Antimetabolite/Analog
Apoptosis
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
2-Chloroadenosine is an adenosine analog, a transporter permeabilizer of nucleoside transporters, and a competitive uridine influx inhibitor (apparent Ki=33 μM). 2-Chloroadenosine binds to nitrobenzylthioinosine with high affinity (apparent Ki=0.18 mM). 2-Chloroadenosine promotes Apoptosis and increases cerebral blood flow. 2-Chloroadenosine has anticonvulsant properties. 2-Chloroadenosine is used to study infection, inflammatory diseases, cancer, blood-related diseases, lung injury, epilepsy, and kidney disease .
|
-
- HY-176065
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective Nav1.2 inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC50 value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode .
|
-
- HY-Y0282
-
|
NSC 77384; Sanibrom 40
|
Environmental Pollutants
|
Neurological Disease
|
|
Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
|
-
- HY-103534R
-
|
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
CI-966 hydrochloride (Standard) is the analytical standard of CI-966 hydrochloride (HY-103534). This product is intended for research and analytical applications. CI-966 hydrochloride is a potent, selective, orally active and brain-penetrant inhibitor of the GABA transporter GAT-1, with IC50s of 0.26 μM and 1.2 μM for hGAT-1, rGAT-1, respectively. CI-966 hydrochloride shows more than 200-fold selectivity over GAT-2, GAT-3, and BGT-3. CI-966 hydrochloride exhibits anticonvulsant and neuroprotective activities .
|
-
- HY-154590
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-N0527
-
|
Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose
|
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species (ROS)
E1/E2/E3 Enzyme
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
- HY-152782
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-15080
-
|
LY 293606
|
iGluR
|
Cardiovascular Disease
Neurological Disease
|
|
GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
|
-
- HY-154357
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-W377455
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (2',5-difluoro-2'-deoxy-1-arabinosyluracil) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-103506R
-
|
NO-711 hydrochloride (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
NNC-711 (Standard) is the analytical standard of NNC-711 (HY-103506). This product is intended for research and analytical applications. NNC-711 (NO-711 hydrochloride) is a potent and selective inhibitor of GAT-1 (GABA transporter 1) with IC50 values of 0.04, 0.38, 171, 1700, 349, 622 μM for human GAT-1, rat GAT-1, rGAT-2, hGAT-3, rGAT-3, hBGT-3, respectively. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity .
|
-
- HY-N0527R
-
|
Penta-O-galloyl-β-D-glucose (Standard); 1,2,3,4,6-Pentagalloyl glucose (Standard)
|
Reference Standards
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
- HY-W050162
-
|
TMCA
|
GABA Receptor
5-HT Receptor
|
Neurological Disease
|
|
(E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABAA/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT2C and 5-HT1A receptor, with IC50 values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy .
|
-
- HY-W013150
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions .
|
-
- HY-N0444
-
|
|
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
|
|
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .
|
-
- HY-101392
-
Harmane
1 Publications Verification
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-W013150R
-
|
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Alpidem (Standard) is the analytical standard of Alpidem (HY-W013150). This product is intended for research and analytical applications. Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
-
- HY-101392A
-
|
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-W013150S
-
|
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Alpidem-d14 is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
-
- HY-179142
-
|
|
COX
TNF Receptor
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC50 of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC50 = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy .
|
-
- HY-12882
-
|
NP-120; RC-61-91
|
iGluR
Adrenergic Receptor
Potassium Channel
Calcium Channel
Influenza Virus
|
Infection
Neurological Disease
|
|
Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease .
|
-
- HY-W700834
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
Inflammation/Immunology
|
|
Harman-d3 is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-W777360
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
Monoamine Oxidase
nAChR
Opioid Receptor
Imidazoline Receptor
GABA Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Harman- 13C2, 15N is 13C and 15N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-12882A
-
|
NP-120 tartrate; RC-61-91 tartrate
|
iGluR
Adrenergic Receptor
Potassium Channel
Calcium Channel
Influenza Virus
|
Infection
Neurological Disease
|
|
Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease .
|
-
- HY-N4267
-
|
|
Calcium Channel
Platelet-activating Factor Receptor (PAFR)
UGT
Leukotriene Receptor
TNF Receptor
PGE synthase
Interleukin Related
|
Cardiovascular Disease
Infection
Inflammation/Immunology
|
|
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca 2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-Y1267
-
|
|
Biochemical Assay Reagents
|
|
Magnesium sulfate is a calcium antagonist and a potent L-type calcium channel inhibitor, as well as a tocolytic. Magnesium sulfate has anti-inflammatory, anticonvulsant, vasodilatory, and neuroprotective effects. Magnesium sulfate can be used in the research of diseases such as preeclampsia/eclampsia .
|
-
- HY-Y1673
-
|
|
Biochemical Assay Reagents
|
|
Potassium bromide, 99% is a salt, widely used as an anticonvulsant and a sedative. Potassium bromide is a redox reagent that can be used to remove peripheral membrane proteins in molecular biology .
|
-
- HY-Y1267D
-
|
|
Biochemical Assay Reagents
|
|
Magnesium sulfate, for cell culture is a bioreagent. Magnesium sulfate is a calcium antagonist and a potent L-type calcium channel inhibitor, as well as a tocolytic. Magnesium sulfate has anti-inflammatory, anticonvulsant, vasodilatory, and neuroprotective effects. Magnesium sulfate can be used in the research of diseases such as preeclampsia/eclampsia .
|
-
- HY-W094475D
-
|
Epsom salts, meets analytical specification of Ph. Eur. BP USP FCC
|
Biochemical Assay Reagents
|
|
Magnesium sulfate heptahydrate, meets analytical specification of Ph. Eur. BP USP FCC (Epsom salts, meets analytical specification of Ph. Eur. BP USP FCC) is currently the anticonvulsant of choice for the prevention and control of eclamptic fits and is also widely used as a tocolytic agent .
|
-
- HY-W094475E
-
|
Epsom salts (Pharmaceutical primary standard, USP)
|
Biochemical Assay Reagents
|
|
Magnesium sulfate heptahydrate, United States Pharmacopeia (USP) Reference Standard (Epsom salts (Pharmaceutical primary standard, USP)) is currently the anticonvulsant of choice for the prevention and control of eclamptic fits and is also widely used as a tocolytic agent .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1932
-
-
- HY-P1334
-
-
- HY-P3960
-
|
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS .
|
-
- HY-114883
-
|
L-Homocarnosine
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-P1334A
-
-
- HY-P1132A
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect .
|
-
- HY-114883A
-
|
L-Homocarnosine TFA
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-P10698
-
|
|
Peptide-Drug Conjugates (PDCs)
LDLR
|
Neurological Disease
|
|
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
|
-
- HY-P1285
-
|
Con-R
|
iGluR
|
Neurological Disease
|
|
Conantokin R (Con-R) is an NMDA receptor peptide antagonist with an IC50 of 93 nM. Conantokin R binds Zn 2+ and Mg 2+ with Kds of 0.15 μM and 6.5 μM, respectively. Conantokin R shows anticonvulsant activity .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0219
-
-
-
- HY-N0527
-
|
Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose
|
Infection
other families
Classification of Application Fields
Anti-aging
Phenols
Polyphenols
Plants
Disease Research Fields
Source Classification
|
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species (ROS)
E1/E2/E3 Enzyme
|
|
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
-
- HY-D0803
-
|
|
Quinones
Classification of Application Fields
Nigella sativa L.
Ranunculaceae
Benzene Quinones
Plants
Inflammation/Immunology
Disease Research Fields
|
Apoptosis
VEGFR
PI3K
Akt
|
|
Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
-
- HY-101392
-
Harmane
1 Publications Verification
|
Alkaloids
other families
Pyridine Alkaloids
Plants
Indole Alkaloids
Source Classification
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
|
Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
-
- HY-114489A
-
-
-
- HY-N6778
-
-
-
- HY-W013507
-
-
-
- HY-113320
-
-
-
- HY-B1302
-
-
-
- HY-12882A
-
-
-
- HY-N1469
-
-
-
- HY-B1122
-
-
-
- HY-W010589
-
-
-
- HY-108964
-
-
-
- HY-B1229
-
-
-
- HY-N0444
-
|
|
Quinones
Structural Classification
Classification of Application Fields
Anthraquinones
Rubiaceae
Phenols
Polyphenols
Plants
Morinda officinalis How
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Reactive Oxygen Species (ROS)
|
|
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .
|
-
-
- HY-W010513
-
-
-
- HY-B1427
-
-
-
- HY-P3960
-
-
-
- HY-Y1373
-
-
-
- HY-N8303
-
|
|
Flavonoids
Flavones
Rutaceae
Plants
Citrus reticulata Blanco
Source Classification
|
ERK
PAK
|
|
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .
|
-
-
- HY-114883
-
-
-
- HY-101392A
-
|
|
Apocynaceae
Alkaloids
Other Alkaloids
Plants
Rauwolfia canescens
Source Classification
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
|
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
-
- HY-N9502
-
-
-
- HY-114883A
-
-
-
- HY-W013507R
-
-
-
- HY-N4267
-
|
|
Cardiovascular Disease
Structural Classification
other families
Classification of Application Fields
Lignans
Phenylpropanoids
Plants
Disease Research Fields
Source Classification
|
Calcium Channel
Platelet-activating Factor Receptor (PAFR)
UGT
Leukotriene Receptor
TNF Receptor
PGE synthase
Interleukin Related
|
|
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca 2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .
|
-
-
- HY-D0803R
-
|
|
Quinones
Structural Classification
Nigella sativa L.
Ranunculaceae
Benzene Quinones
Plants
|
Reference Standards
Apoptosis
VEGFR
PI3K
Akt
|
|
Thymoquinone (Standard) is the analytical standard of Thymoquinone. This product is intended for research and analytical applications. Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
-
- HY-Y1373R
-
-
-
- HY-114489B
-
-
-
- HY-N0219R
-
-
-
- HY-N0527R
-
|
Penta-O-galloyl-β-D-glucose (Standard); 1,2,3,4,6-Pentagalloyl glucose (Standard)
|
Structural Classification
other families
Phenols
Polyphenols
Plants
Source Classification
|
Reference Standards
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species (ROS)
|
|
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
-
- HY-108964R
-
-
-
- HY-N9502R
-
-
-
- HY-B1122R
-
-
-
- HY-W010589R
-
-
-
- HY-N1516R
-
-
-
- HY-N16538
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0246S
-
|
|
|
Carbamazepine-d10 is the deuterium labeled Carbamazepine. Carbamazepine (CBZ), a sodium channel blocker, is an anticonvulsant agent .
|
-
-
- HY-B0246S2
-
|
|
|
Carbamazepine-d8 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent, with an IC50 of 131 μM .
|
-
-
- HY-B0495S4
-
|
|
|
Lamotrigine- 13C3 is the 13C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
-
- HY-123193S
-
|
|
|
Avizafone-d5 dihydrobromide is the deuterium labeled Avizafone dihydrobromide . Avizafone (Pro-diazepam) dihydrobromide, a pro-drug of Diazepam, is an anticonvulsant agent. Avizafone dihydrobromide can be used as an antidote of nerve agent poisoning. In vivo, Avizafone is rapidly hydrolyzed by aminopeptidase to produce lysine and diazepam. Avizafone dihydrobromide has research areas including neurological disease, such as epilepsy.
|
-
-
- HY-B0246S1
-
|
|
|
Carbamazepine-d2 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent.
|
-
-
- HY-Y1373S1
-
1 Publications Verification
|
|
Cyclohexanecarboxylic acid-d11 is the deuterium labeled Cyclohexanecarboxylic acid . Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .
|
-
-
- HY-114703S1
-
|
|
|
Eslicarbazepine-d4 (BIA 2-194-d4) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
|
-
-
- HY-B0495S5
-
|
|
|
Lamotrigine-d3 is the deuterium labeled Lamotrigine . Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
-
- HY-B0688S
-
|
|
|
Dapsone-d8 is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide antibiotic with antibacterial, antigenic and anti-inflammatory activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone can be used as an anticonvulsant and also in the research of skin and glioblastoma diseases .
|
-
-
- HY-B0495S3
-
|
|
|
Lamotrigine- 13C2, 15N is the 13C and 15N labeled Lamotrigine . Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
-
- HY-B0246S4
-
|
|
|
Carbamazepine-d4 (CBZ-d4) is the deuterium labeled Carbamazepine (HY-B0246) . Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na +, Ca 2+, and K + channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.
|
-
-
- HY-108506S2
-
|
|
|
Licarbazepine-d4-1 is deuterium labeled Licarbazepine. Licarbazepine (BIA 2-005; GP 47779)?is a?voltage-gated sodium channel?blocker?with?anticonvulsant?and?mood-stabilizing?effects .
|
-
-
- HY-B0211S1
-
|
|
|
Riluzole- 13C6 (PK 26124- 13C6) is 13C labeled Riluzole. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na + channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.
|
-
-
- HY-113320S
-
|
|
|
Etiocholanolone-d5 is the deuterium labeled Etiocholanolone. Etiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity . Etiocholanolone is a less potent?neurosteroid positive allosteric modulator?(PAM) of the GABAA?receptor than its?enantiomer form .
|
-
-
- HY-W013378S
-
|
|
|
Carbamazepine 10,11 epoxide-d2 is the deuterium labeled Carbamazepine 10,11 epoxide . Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
|
-
-
- HY-B0114S
-
|
|
|
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0495S1
-
|
|
|
Lamotrigine- 13C,d3 is the 13C- and deuterium labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
-
- HY-B1184S1
-
|
|
|
Mephenytoin-d5 is the deuterium labeled Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
|
-
-
- HY-U00315S
-
|
|
|
Gidazepam-d5 is a deuterium labeled Gidazepam. Gidazepam is an agonist of GABA receptor channels (GABA RCs), and has anticonvulsant effect .
|
-
-
- HY-B1184S2
-
|
|
|
Mephenytoin-d8 is the deuterium labeled Mephenytoin . Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
|
-
-
- HY-B1184S
-
|
|
|
(Rac)-Mephenytoin-d3 is a labelled racemic Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
|
-
-
- HY-108506S1
-
|
|
|
Licarbazepine-d4 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-108506S
-
|
|
|
Licarbazepine-d3 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-B1642S
-
|
|
|
Ethotoin-d5 is the deuterium labeled Ethotoin . Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin .
|
-
-
- HY-W722128
-
|
|
|
Olivetolic acid-d9 is the deuterium labeled Olivetolic acid (HY-W090292). Olivetolic acid is a biosynthetic precursor of cannabinol acid (CBGA). Olivetolic acid has anticonvulsant activity .
|
-
-
- HY-B1184S3
-
|
|
|
Mephenytoin-13C,d3 is a deuterated labeled Mephenytoin . Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
|
-
-
- HY-114703S
-
|
|
|
Eslicarbazepine-d3 (BIA 2-194-d3) is the deuterium labeled Eslicarbazepine (HY-114703). Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
|
-
-
- HY-B0184S1
-
|
|
|
Felbamate-d5 is the deuterium labeled Felbamate . Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
|
-
-
- HY-B0184S
-
|
|
|
Felbamate-d4 (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
-
- HY-108506S4
-
|
|
|
Licarbazepine-d8 (BIA 2-005-d8) is deuterium labeled Licarbazepine. Licarbazepine (BIA 2-005; GP 47779)?is a?voltage-gated sodium channel?blocker?with?anticonvulsant?and?mood-stabilizing?effects .
|
-
-
- HY-B1657AS
-
|
|
|
Fosphenytoin-d10 (disodium) is deuterium labeled Fosphenytoin (disodium). Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
-
-
- HY-B0339S
-
|
|
|
Primidone-d5 is the deuterium labeled Primidone. Primidone is the orally active inhibitor for TRPM3 (IC50 = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent .
|
-
-
- HY-B0211S
-
|
|
|
Riluzole- 13C, 15N2 is the 13C and 15N labeled Riluzole . Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM .
|
-
-
- HY-113320S1
-
|
|
|
Etiocholanolone-d2 is the deuterium labeled Etiocholanolone. Etiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity . Etiocholanolone is a less potent?neurosteroid positive allosteric modulator?(PAM) of the GABAA?receptor than its?enantiomer form .
|
-
-
- HY-B0114S1
-
|
|
|
Oxcarbazepine-d4-1 is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S3
-
|
|
|
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S2
-
|
|
|
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0696S
-
|
|
|
Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-B0696AS
-
|
|
|
Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-16579AS2
-
|
|
|
Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
|
-
-
- HY-A0042S
-
|
|
|
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
-
- HY-B0495S7
-
|
|
|
Lamotrigine- 13C (LTG- 13C) is 13C labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
-
- HY-W012481S
-
|
|
|
Nirvanol-d5 (Ethylphenylhydantoin-d5) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
-
- HY-B1283S
-
|
|
|
Mephenesin-d3 is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .
|
-
-
- HY-B0162S
-
|
|
|
Ivabradine-d6 is the deuterium labeled Ivabradine . Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
|
-
-
- HY-103392S
-
|
|
|
Stiripentol-d9 is the deuterium labeled Stiripentol. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Kis of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively .
|
-
-
- HY-B0495S
-
|
|
|
Lamotrigine- 13C3,d3 is the 13C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
-
- HY-A0042S1
-
|
|
|
Rufinamide- 15N,d2 (CGP 33101- 15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
-
- HY-B0495S8
-
|
|
|
Lamotrigine- 13C7, 15N (LTG- 13C7, 15N) is 13C and 15N labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .
|
-
-
- HY-W010589S2
-
|
|
|
L-2-Aminobutyric acid-d6 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
|
-
- HY-W010589S
-
|
|
|
L-2-Aminobutyric acid-d3 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
|
-
- HY-A0042S2
-
|
|
|
Rufinamide- 15N,d2-1 (CGP 33101- 15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-B0495S6
-
|
|
|
Lamotrigine- 13C2, 15N2,d3 is 15N and deuterated labeled Lamotrigine (HY-B0495). Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
|
-
- HY-W013378S2
-
|
|
|
Carbamazepine 10,11-epoxide- 13C,d2 is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a 13C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
|
-
- HY-W013150S
-
|
|
|
Alpidem-d14 is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
-
- HY-W777360
-
|
|
|
Harman- 13C2, 15N is 13C and 15N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-Y1373S
-
|
|
|
Cyclohexanecarboxylic acid-d1 is the deuterium labeled Cyclohexanecarboxylic acid . Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .
|
-
- HY-158252S
-
|
|
|
Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696S1
-
|
|
|
Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-W708332
-
|
|
|
3-Methylvaleric acid-d11 is the deuterium labeled 3-Methylvaleric Acid (HY-W010513). 3-Methylvaleric Acid is a branched alkanoic acid. 3-Methylvaleric Acid can be utilized by Pseudomonas citronettotis as a sole carbon source for its growth. 3-Methylvaleric Acid derivatives exhibit anti-hyperalgesic and anticonvulsant activities .
|
-
- HY-W700834
-
|
|
|
Harman-d3 is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-152782
-
|
|
|
Azide
|
|
4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152476
-
|
|
|
Alkynes
|
|
3’-β-C-Ethynyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-β-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154736
-
|
|
|
Alkynes
|
|
N3-(Butyn-3-yl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . N3-(Butyn-3-yl)uridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152985
-
|
|
|
Azide
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-Azido-3’-deoxy-4-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154590
-
|
|
|
Azide
|
|
2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154357
-
|
|
|
Azide
|
|
4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-152358
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Methyl-2’-O-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-134337
-
|
|
|
Phosphoramidites
Uracil
|
|
5'-O-DMTr-3'-O-methyl uridine-3'-CED-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152732
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154285
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-(2-Methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154466
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-48973
-
|
|
|
Phosphoramidites
Uracil
|
|
2'-Fluoro-2'-deoxy-ara-U-3'-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154358
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-alpha-C-Allyl-2’,3’-bis(O-t-butyldimethylsilyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154492
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-4’,5’-didehydro-5’-deoxyuridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154582
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Naphthyl-beta-methylaminocarbony-3’-O-acetyl-2’-O-methyl-5’-O-DMTr-uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152782
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-W020098
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2'-C-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154488
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′-O-[(1,1-Dimethylethyl)dimethylsilyl]-2′-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154517
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Cyanoethyl-5’-O-(4,4’-dimethoxytrityl)-2’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152755
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-Cyanouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152764
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-α-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152777
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’(R)-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152299
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(t-Butyloxycarbonylmethoxy)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154735
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Allyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152388
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-beta-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152665
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(β-D-Xylofuranosyl)uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152970
-
|
|
|
Phosphoramidites
Uracil
|
|
7'-O-DMT-morpholino uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154734
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(4-Nitrobenzyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W557556
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',5'-Bis-O-(triphenylMethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152677
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(2-Methoxy)ethyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154217
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′,5′-Bis-O-(triphenylmethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152529
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-C-Methyl-5-methoxyuridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152522
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Fluoro-4’-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154738
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[3-(tert-Butoxycarbonyl)amino]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152783
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’(R)-C-Methyl-5-fluorouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152969
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152779
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methoxy-5’(R)-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152798
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Iodo-2’-β-C-methyl uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154737
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[(Pyrid-4-yl)methyl]uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152681
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[(Tetrahydro-2-furanyl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152463
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4′-C-2-Propen-1-yluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152683
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[(Pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152574
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Amino-2’-deoxy-2’-O-methyluridine hydrochloride is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152674
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Deoxy-2′-fluoro-5-methoxy-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154560
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-acetyl-N3-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152363
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Methyl-2’-O-(2-methoxyethyl)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154173
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-(t-Butyldimethylsilyl)-2’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154813
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′,5′-Di-O-acetyl-2′-deoxy-2′-fluorouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-49199
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3',5'-Tri-O-(t-butyldimethylsilyl)-4'-C-hydroxymethyl uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154410
-
|
|
|
Phosphoramidites
Uracil
|
|
5’-O-DMT-2’-deoxy-2’-fluoro-β-D-arabinouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152691
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154175
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-[6-(Diethoxyphosphinyl)-2-O-(2-methoxyethyl)-β-D-ribo-hexofuranosyl]uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152792
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154552
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-5’-O-benzoyl-3’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154647
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(2S)-[2-(tert-Butoxycarbonyl)amino-3-(tert-butoxy carbonyl)]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154652
-
|
|
|
Nucleoside Analogs
|
|
1-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-2,4(1H,3H)-pyrimidinedione is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
- HY-152476
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-β-C-Ethynyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-β-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154736
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(Butyn-3-yl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . N3-(Butyn-3-yl)uridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-77650
-
|
4'-Azidouridine
|
|
Nucleoside Analogs
Uridine
|
|
4'-C-azidouridine (4'-Azidouridine) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4'-C-Azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152985
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-Azido-3’-deoxy-4-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154590
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154357
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: